
Citation: Laura Grassini. Statistical features and economic impact of Covid-19[J]. National Accounting Review, 2023, 5(1): 38-40. doi: 10.3934/NAR.2023003
[1] | Michael T. Fasullo, Mingzeng Sun . Both RAD5-dependent and independent pathways are involved in DNA damage-associated sister chromatid exchange in budding yeast. AIMS Genetics, 2017, 4(2): 84-102. doi: 10.3934/genet.2017.2.84 |
[2] | Carina Ladeira, Susana Viegas, Mário Pádua, Elisabete Carolino, Manuel C. Gomes, Miguel Brito . Relation between DNA damage measured by comet assay and OGG1 Ser326Cys polymorphism in antineoplastic drugs biomonitoring. AIMS Genetics, 2015, 2(3): 204-218. doi: 10.3934/genet.2015.3.204 |
[3] | Vladlena Tiasto, Valeriia Mikhailova, Valeriia Gulaia, Valeriia Vikhareva, Boris Zorin, Alexandra Kalitnik, Alexander Kagansky . Esophageal cancer research today and tomorrow: Lessons from algae and other perspectives. AIMS Genetics, 2018, 5(1): 75-90. doi: 10.3934/genet.2018.1.75 |
[4] | Britta Muster, Alexander Rapp, M. Cristina Cardoso . Systematic analysis of DNA damage induction and DNA repair pathway activation by continuous wave visible light laser micro-irradiation. AIMS Genetics, 2017, 4(1): 47-68. doi: 10.3934/genet.2017.1.47 |
[5] | Mrinalini Tiwari, Suhel Parvez, Paban K Agrawala . Role of some epigenetic factors in DNA damage response pathway. AIMS Genetics, 2017, 4(1): 69-83. doi: 10.3934/genet.2017.1.69 |
[6] | Mi Young Son, Paul Hasty . Homologous recombination defects and how they affect replication fork maintenance. AIMS Genetics, 2018, 5(4): 192-211. doi: 10.3934/genet.2018.4.192 |
[7] | Asaad M Mahmood, Jim M Dunwell . Evidence for novel epigenetic marks within plants. AIMS Genetics, 2019, 6(4): 70-87. doi: 10.3934/genet.2019.4.70 |
[8] |
Hossein Mozdarani, Sohail Mozdarani .
De novo cytogenetic alterations in spermatozoa of subfertile males might be due to genome instability associated with idiopathic male infertility: Experimental evidences and Review of the literature . AIMS Genetics, 2016, 3(4): 219-238. doi: 10.3934/genet.2016.4.219 |
[9] | Huong Thi Thu Phung, Hoa Luong Hieu Nguyen, Dung Hoang Nguyen . The possible function of Flp1 in homologous recombination repair in Saccharomyces cerevisiae. AIMS Genetics, 2018, 5(2): 161-176. doi: 10.3934/genet.2018.2.161 |
[10] | Jasmin Knopf, Mona HC Biermann, Luis E Muñoz, Martin Herrmann . Antibody glycosylation as a potential biomarker for chronic inflammatory autoimmune diseases. AIMS Genetics, 2016, 3(4): 280-291. doi: 10.3934/genet.2016.4.280 |
There is increasing evidence that one of the main difficulties in trying to control the ongoing COVID-19 epidemic is the presence of a large cohort of asymptomatic infectives [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16]. This feature was first noted in the analysis of passengers of evacuation flights from Wuhan, see e.g., [17,18], and on the Crown Princess cruise ship [19], but in these circumstances the asymptomatic cases could easily be thought to be just cases which had not yet developed symptoms.
So the first confirmation of this characteristic of COVID was obtained in the large scale study of one of the first infection foci in Italy, that of Vò Euganeo near Padua; here the whole population (about 3, 000 people) of the village were tested twice – at one week distance – for the virus, and a significant number of asymptomatic infectives was detected [20].
We stress that it is correct to speak of asymptomatic infectives and not just carriers. In fact, it is by now thought that they are as infective as symptomatic ones in terms of viral charge [1,13,14,15] – and of course potentially even more dangerous as the absence of symptoms leads to a low level of precautions.
One of the consequences of this fact is that the registered infectives, those known to the national health systems and thus isolated and monitored, are only a part of the total pool of infectives.
The initial estimates were that registered infectives would be between 1/3 and 1/4 of the actual infectives [21]; there have been early claims by the British Government scientific advisers [22] that this ratio could be as little as 1/10. In a recent contribution [23] Li et al. estimate that only about 1/7 of the infections are detected and can thus be isolated. More recently, other studies have suggested that the fractions of undetected infections could be even higher [24,25].
This is obviously a very relevant matter, both to understand the epidemic dynamic and to design concrete actions to counter the epidemic spreading.
The goal of this note is two-fold: on the one hand we want to develop a simple general model to take into account the presence of asymptomatic infectives; on the other hand, we want to apply this to the ongoing COVID-19 epidemic, in particular considering the situation in Italy, i.e., in the first European country to be heavily struck by COVID.
One of the problems faced in this situation is that at the start of the epidemic due to a new pathogen, one has to estimate the infectivity of this, and more generally the parameters in any model used to describe the epidemic. This will have to be considered in some detail.
The estimate of the fraction of asymptomatic infectives is one of the problems encountered in this sense. In the case of COVID in Italy, our estimate – based on a fit of the epidemiological data by the model, see Sections 7 and 8 below – is that only 10% of infectives are symptomatic; this also means that in the early phase of the epidemic, in particular before the relevance of asymptomatic transmission was fully understood and asymptomatic infectives were searched for, only 10% of the infectives (at best, i.e., assuming that symptoms were properly related to COVID) were registered by the health system.
The plan of the paper is as follows. We start by recalling some basic facts about the well known SIR model (Section 2), and discuss in more detail how this can be fitted against the data available in the first phase of an epidemic (Section 2.5).
Beside all the obvious limitations of SIR-type models, the standard SIR – as recalled above – does not take into account the special features introduced by the presence of a large set of asymptomatic infectives, i.e., the aspect we want to focus on in this contribution. We will therefore develop a SIR-type model taking into account the presence of asymptomatic infectives, and the substantially long time these spend being infective and not isolated; this is called A-SIR, the A standing indeed for asymptomatic (Section 3). We also repeat in this context the discussion on how the model parameters can be estimated on the basis of the early stages of the epidemics in that context, see Sections 3.3 and 3.4 (we will find that parameters present in both the two models are fitted in the same way from available data).
We will then come, in Section 4, to one of the main points of our study, i.e., comparing the different predictions of the standard SIR and of the new A-SIR model for a given set of initial-stage epidemiological data (which are coded by the coefficients of a function fitting them). This comparison is made by means of numerical simulations for realistic values of the parameters, but with no reference yet to any concrete case.
One of our main interests is in understanding how relevant it can be to uncover asymptomatic infectives and promptly isolate them; we then study (numerically) how the dynamics is affected by a reduction of the removal time for this class (Section 5), as could be obtained by a contact tracing and testing campaign [20].
The discussion so far considered a generic infection (providing long-term immunity to recovered patients) with a large set of asymptomatic infectives. In the second part of the paper, we apply our model to the COVID-19 epidemics in Italy (Section 6). In order to do this we first of all have to estimate the model parameters from data in the initial phase; to this aim we use the data from the first half of March and determine our best fit of the epidemiological data through a two-step procedure. This first determines relations between the parameters, reducing these to expressions in terms of the the removal times for symptomatic and asymptomatic patients, i.e., on parameters β and η (see below), and this is obtained based on data for the first week; then data for the second week are used to fit these latter parameters. We do of course also compare these fits with the data in the initial phase, see Section 7. The A-SIR model outperforms the standard SIR model in this respect.
We will naturally also consider the subsequent development of the COVID-19 epidemics, but in order to do this we will have to consider the different sets of measures taken on March 8 and March 23 by the Italian Government and based on social distancing; these will be taken into account by means of a reduction of the contact rate parameter in the model. The amount r of reduction will be a fitted parameter (Section 8).
With a suitable choice of r, we get a rather good agreement between the dynamic of our model and epidemiological data up to mid-May (i.e., the time of writing of this paper), see Figures 9 and 10.
We will end the paper by a discussion of some relevant general points and by conclusions (Section 9); we anticipate here the main ones:
(i) there is a marked difference between the standard SIR dynamics and the dynamics of the A-SIR model, i.e., the one taking into account the presence of a large class of asymptomatic infectives;
(ii) in the case of the COVID-19 epidemic in Italy, assuming a ratio of symptomatic to total infections of ξ=1/10 yields a good agreement between the model and epidemiological data.
We stress that our estimate of the ratio ξ is – as far as we know – the first one given on the basis of a theoretical model and not just of statistics. On the other hand, it agrees with the current estimates given by health agencies and physicians.
It is maybe useful to also anticipate what are our conclusions about the consequences of the "marked difference" mentioned in item (i) above. We find – in Section 4 – that a standard SIR analysis in a situation where the A-SIR model applies, would make three substantial errors: (a) The number of (symptomatic) infectives needing Hospital care would be over-estimated; (b) The time before the epidemic peak - so the time available to prepare the health system to face it - would be over-estimated; (c) The number of people not touched by the epidemic wave, so still in danger if a second wave arises, would be over-estimated. It is rather clear that each of these errors would have substantial practical consequences.
In an Appendix, we will also discuss how the presence of asymptomatic infectives affects our estimate of the basic reproduction number (usually denoted as R0); this might explain why many national health agencies were caught short by the rapid rise in COVID-19 cases.
Our discussion will include a number of small deviations from the central development; these will be given in the form of Remarks. The symbol ⊙ will signal the end of a Remark.
The classical SIR model for the dynamics of an infective epidemic providing permanent immunity to those who have already been infected and recovered [26,27,28,29,30,31,32,33,34] describes a homogeneous and isolated population of N individuals by partitioning them into three classes: each individual can be either susceptible (S), infected and infective (I), or removed (R) from the epidemic dynamics (that is, either recovered, dead, or isolated). We denote by S(t), I(t) and R(t) the populations of these classes at time t; by assumption, S(t)+I(t)+R(t)=N for all t.
The model is described by the equations
dS/dt=− αSIdI/dt=αSI − βIdR/dt=βI . | (2.1) |
In the following, the parameter
γ= β/α | (2.2) |
will have a special relevance.
This model is well known, but we recall here some of its features both for the sake of completeness and with the purpose of comparing these with those for the new model to be introduced below. Further detail on the SIR model can be found in textbooks [30,31,32,33,34].
We would like to stress a relevant general point. As mentioned above, the SIR model (and more generally SIR type models) assume that we have an isolated population, and that individuals react to the pathogen and interact socially in a homogeneous way. In physicists' language, this is a mean field theory, i.e., in common language all individuals characteristics are erased, and real individuals are replaced by an "ideal" type corresponding to the average over the population. It goes without saying that these assumptions are not only radical, but also non realistic: Individuals in any population differ for age, health state, and contact network. On the other hand, when – as in a starting epidemic which is overwhelming the sanitary system – we have scarce data (and available data are not organized in the way they should be in a laboratory experiment) it has the advantage of providing a qualitative description, whose quantitative predictions can be compared with experiment also if fed with the scarce and rough available data.
In other words, we agree that e.g., an epidemic model on a network [35,36,37] would be more realistic, but on the one hand we doubt that the available data allow to identify the existing network at this stage*, and on the other hand we would not like to have predictions which depend on the (unknown) features of this network. We will thus be satisfied with working with SIR-type models.
* The health agencies have studied the diffusion of influenza over many years, and this presumably allows to reconstruct some features of the diffusion network (e.g., at department level); but surely the extraordinary alarm caused by COVID emergence has modified all kinds of interpersonal relations and all usual travel patterns among countries or among regions in the same country.
Remark 1. Note that according to Eq (2.1), an infected individual is immediately infective. For most infections this is not realistic, of course, but if the delay is substantially smaller that the characteristic removal time β−1, we get a good approximation and still keep to a very simple model with all its advantages for qualitative discussion. The same remark will also apply to the A-SIR model, to be introduced and discussed in Section 3 below.
Note also that the SIR equations (2.1) stipulate that we have a constant population; in practical terms, this means we are considering an epidemic developing over a short enough timespan, i.e., such that one can disregard deaths and new births. In particular the latter provide new fuel to the susceptible class and thus if the epidemic goes on for a long time related terms should be included in the model; this may led to the presence of an endemic state [30].
It is immediately apparent that in the SIR model the number of infected will grow as long as
S > γ ; | (2.3) |
thus γ is also known as the epidemic threshold. The epidemic can develop only if the population is above the epidemic threshold.
The ratio
R0 := S0γ | (2.4) |
is known as the basic reproduction number (BRN), or also basic reproduction rate, and is an estimate of how many new infections are originated from a single infective in the initial phase of the epidemic [38,39,40]. (In fact, the first equation in (2.1) says that there are αSI(δt) new infections in a time interval δt, and each infective is such for an average time β−1.)
The parameters α and β describe the contact rate and the removal rate; they depend both on the characteristics of the pathogen and on social behavior. For example, a prompt isolation of infected individuals is reflected in raising β, a reduction of social contacts is reflected in lowering α, and both these actions raise the epidemic threshold γ. If this is raised above the level of the total population N, the epidemic stops (which means the number of infected individuals starts to decrease, albeit new individuals will still be infected). The same effect can be obtained by reducing the population N (keeping α and β constant), i.e., by partitioning it into non-communicating compartments, each of them with a population below the epidemic threshold.
Remark 2. Albeit strictly speaking these predictions only hold within the SIR model, and surely the exact value of the threshold refers to this model only, the mechanism at play is rather general, and similar behaviors are indeed predicted by all kind of epidemic models.
One can easily obtain the relation between I and S by considering the equations governing their evolution in (2.1) and eliminating dt; this provides
dI/dS = −1 + γ/S . | (2.5) |
Upon elementary integration this yields (note we always write "log" for the natural logarithm)
I = I0 + (S0−S) + γlog(S/S0) ; | (2.6) |
with I0,S0 the initial data for I(t) and S(t); unless there are naturally immune individuals (which is not the case for new infections), S0=N−I0≃N.
As we know (see above) that the maximum I∗ of I will be reached when S=γ, we obtain from (2.6) an estimate of the level of this maximum; i.e., writing γ=σN (with σ<1) this reads
I∗ = [1 − σ − σlog(1/σ)] N . | (2.7) |
Note that we do not have an analytical estimate of the time needed to reach this maximum; see below.
It follows from (2.7) that increasing γ, even if we do not manage to take it above the population N, leads to a reduction of the epidemic peak; if we are sufficiently near to the epidemic threshold, this reduction can be rather relevant also for a relatively moderate reduction of α and thus increase of γ.
The formula (2.6) also allows to obtain an estimate for another parameter describing the severity of the epidemics, i.e., the total number of individuals R∞ which are infected over the whole span of the epidemics. In fact, the epidemic is extinct (at an unknown time t=T0) when I=0; the number of susceptibles S∞ at this stage is provided there by the (lower) root of the equation
I0 + (S0−S) + γlog(S/S0) = 0 ; |
as noted above I0≃0, S0≃N, and we can simply look at
(N−S∞) + γlog(S∞/N) = 0 . | (2.8) |
This is a transcendental equation, but it is easily solved numerically if γ is known. The sought for number of overall infected individuals R∞ is of course provided by
R∞ = N−S∞ . | (2.9) |
Remark 3. In the case of a small epidemic, we have S∞/N≃1, and we can expand the logarithm in a Taylor series; in this way we get S∞=(3−2N/γ)N. See also Section 2.3 below.
Another key quantity is the speed at which the epidemic dynamics develops, and in particular the time t∗ at which I reaches its maximum value I∗, and the time t∞ needed for I to get to zero (and S(t∞)=S∞, of course). In this case one can not get an analytical estimate, but it is possible to describe how this depends on the values of α and β for a given population level N and initial conditions {S0,I0,R0}. In fact, the equations (2.1) are invariant under the scaling
α→λα , β→λβ , t→λ−1t . | (2.10) |
(Note that the inverse scaling of β and t is enforced by the very physical meaning of β, which is the inverse of the characteristic time for the removal of infectives.)
The meaning of (2.10) is that if we manage to reduce α by a factor λ, even in the case β is also reduced and thus γ remains unchanged, the speed of the epidemic dynamics is also reduced by a factor λ. On the other hand, it is clear from the equation for dS/dt in (2.1) that reducing α reduces the speed at which new infective appear; if the removal rate β is unchanged, this will make that I grows slower and reaches a lower level. See Figure 1 in this regard.
The SIR equations are nonlinear, and an analytical solution of them turns out to be impossible; they can of course be numerically integrated with any desired precision if the initial conditions and the value of the parameters are known.
In the case of well known infective agents (e.g., for the influenza virus) the parameters are known with good precision, and indeed Health Agencies are able to forecast the development of seasonal epidemics with good precision. Unfortunately this is not the case when we face a new virus, as for COVID-19.
Moreover, when we first face a new virus we only know, by definition, the early phase of the dynamics, so parameters should be extracted from such data. (We stress that the parameters depend not only on the pathogen agent, but also on the social structure and organization of the country, e.g., on its population density, restrictive measures, and sanitary system; thus they are different in each country, and data for different countries can not be pooled together to have a wider statistics.) We will thus concentrate on this initial phase, with I(t) and R(t) rather small, and try to obtain approximate analytical expressions for the dynamics; the purpose will be to estimate the parameters α and β – and thus also the epidemic threshold γ – in this case.
Remark 4. Albeit we do not expect, for various reasons, the SIR model to provide a good description of the dynamics when the infection produces a large number of asymptomatic carriers, having an estimate of these parameters will be needed to compare the predictions which one would extract from the standard SIR model in such circumstances with those obtained by the modified model we will consider later on, see Section 3. As for the reasons to expect the SIR model to perform poorly in the presence of a large set of asymptomatic carriers, these have to do both with the practical implementation and with intrinsic limitations of the model. As for the first type, in practice we estimate the model's parameters by epidemiological data based only on registered (thus mostly symptomatic) infectives; if these are only a small part of the infectives, the estimates of the parameters will be grossly different from the true ones. As for the intrinsic limitations of standard SIR in this setting, we will come back to this point at the end of Section 3.1, in Remark 12.
In the case of "small epidemics" there is a way to obtain an analytical expression for the solutions to the SIR equations or more precisely to the approximate equations valid in the limit of small R/γ; this is associated to the names of Kermack and McKendrick [26,27,28], and we will therefore refer to it as the KMK method (This is very classical, and is discussed here for the sake of completeness.).
What matters more here, the expression obtained in this way is also an analytical expression holding in the initial phase of any epidemics, small or large, i.e., – as we will discuss in a moment – until R(t)≪γ.
Thus such an analytical expression can be compared to early epidemiological data and used to estimate the unknown parameters α and β, and hence the fundamental parameter γ. Once this is done, the model can be studied numerically (or, if we are – as has to be hoped – in the favorable situation where N≃γ, one can set predictions on the basis of the "small SIR epidemic" model) – recalling of course that the SIR model itself is far too simple to be reliable in a situation where the actions undertaken have heavy consequences on public health – in order to have some kind of estimate of the length of the epidemics and of other relevant outcomes, such as the numbers I∗ and J∞ considered above.
It should be noted that we do not have full knowledge about the number of infective people at each time; the best we can have is the number of people who are hospitalized or however registered by the health system. Assuming that infective people are immediately isolated, this provides an estimate (actually from below) of R(t). Thus we should be able to compare the predictions for the removed class with epidemiological data, and in order to do this we should focus on R(t). We stress that his problem was already clear to Kermack and McKendrick [26,27,28], see e.g., the discussion in Murray [30], and that we will basically follow their idea albeit with a relevant difference, which will allow for a simpler fit of the data.
Putting together the equations for S and for R in (2.1), we have dS/dR=−S/γ, which of course provides
S(R) = S0 e−(R−R0)/γ . | (2.11) |
We can proceed similarly with the equations for I and for R, getting dI/dR=−1+S/γ, where now S should be thought of as a function of R through (2.11). Solving this equation we get
I(R) = I0 + S0 (1−exp[−(R−R0)/γ]) − (R−R0) . | (2.12) |
We are however interested in the temporal dynamics of the model. In order to do this, we can substitute for I=I(R) using (2.12) in the equation for dR/dt in (2.1); moreover we will look at the variable
P(t) := R(t) − R0 , | (2.13) |
which of course satisfies P(0)=0 and dP/dt=dR/dt. In this way we have
I(P) = I0 + S0 (1−e−P/γ) − P . | (2.14) |
Plugging now this into the third equation of (2.1), we finally get
dPdt = β [I0 + S0(1−e−P/γ) − P] . | (2.15) |
This is a transcendental equation and can not be solved exactly. However, as long as P/γ≪1, i.e., as long as R(t) is well below the epidemic threshold, we can replace the exponential by (a suitable truncation of) its Taylor series expansion.
Remark 5. In textbook discussions, it is usually required to consider a second order Taylor expansion; this guarantees that counter-terms preventing the exponential explosion of R(t) (and thus the violation of the condition R(t)≪γ) are present, and allows to obtain an analytical expression for R(t) – solution of the approximate SIR equations for R/γ≪1 – valid at all times. This is, more precisely, in the form
R(t) = α2S0 [ϕ + k1 tanh[k1β2t − k2] ] , | (2.16) |
where we have written ϕ:=(S0/γ−1) and k1 and k2 are explicitly given by
k1=√ϕ2+2(S0/γ2)(N−S0); k2=k−11arctanh(ϕ) . | (2.17) |
As we assume there is no natural immunity, we can take S0≈N, obtaining k1≈ϕ and hence slightly simpler complete expressions.
Remark 6. In particular, in this case the maximum of R′(t) – and hence of I(t), see (2.1) – is obtained at time
t∗ = 2 arctanh(ϕ)β ϕ2 ; |
as our result holds for the "small epidemics", ϕ is small and we can write
˜t∗ ≃ 2βϕ + 23ϕβ . |
Note that t∗ is therefore rapidly decreasing with ϕ (for small ϕ). On the other hand, looking back at (2.7), and noticing that in terms of the notation used there σ=1/(1+ϕ), we obtain immediately that I∗ grows with ϕ.
Remark 7. This also means that if one would be able to tune the parameters α and β (and hence ϕ) there would be a contrast between trying to have a low I∗ and hence a small ϕ, and trying not to have the epidemic running for too long – which can be devastating on social and economic grounds. If, on the other way, the priority from the temporal point of view is on slowing down the epidemic, e.g., to have the time to prepare the health system facing the peak, a small ϕ should be pursued.
We have seen in Section 2.3 that a full solution of the KMK model is equivalent to a full solution of Eq (2.15), and if we have a small epidemic then the solution is well approximated – at all times – by (2.16).
Here we are less ambitious: When the epidemic is just starting, we can in any case only fit the initial phase of the epidemic, which shows an exponential increase of R(t), and correspondingly we can expand the exponential in (2.15) at first order in P/γ. This yields the equation
dPdt = β [I0 + (S0γ−1) P] , | (2.18) |
with initial condition P(0)=0. This is immediately solved to give
P(t) = I0 exp[β(S0/γ−1)t] − 1(S0/γ−1) . | (2.19) |
Introducing the parameter, which we stress is now not assumed to be small,
ϕ := S0γ − 1 , | (2.20) |
the above is more simply written as
P(t) = I0ϕ [eβϕt − 1] , | (2.21) |
and finally we get
R(t) = R0 + I0ϕ [eβϕt − 1] . | (2.22) |
As expected this – at difference with (2.16) – is not saturating but just expanding exponentially, and thus cannot be valid for all times, but only for t sufficiently small (even for small ϕ).
The expression (2.22) can then be expanded in series to give the small t expression of the solution, which can be fitted against experimental data thus determining (some of) the parameters, see Section 2.5 below.
Remark 8. It is relevant for the following of our discussion to note that the solution (2.22) can be obtained also in a different way, i.e., noticing that in the initial phase of the epidemic the number of susceptibles vary very little and can thus be considered as constant, S(t)≃S0. Within his approximation, and writing again ϕ=(S0/γ−1), the SIR equations reduce to
{dI/dt = βϕIdR/dt = βI; | (2.23) |
this is a linear system, and it is promptly solved to yield indeed (2.22).
Note this approach is actually simpler than the one followed above (so the reader may wonder why we have not taken this immediately), but on the one hand the procedure given above is along the lines of the tradition of SIR analysis, and on the other hand having seen that derivation gives us more confidence that a rough approach as this one provides the same results as a more refined one; this will be of use dealing with more complex models, where the Kermack-McKendrick approach can not be followed, see Section 3.3 below.
Note that the solution (2.22) depends on three parameters, i.e., β, I0 and ϕ, which in turn depends on the known number S0≃N and on the unknown parameter γ. None of the parameters {β,ϕ,I0} is known, but β can be directly estimated on the basis of medical data as it corresponds to the inverse of the typical removal time (for trivial infections, this corresponds to the time of healing; in the case of COVID it is the time from infection to isolation), and similarly once we fix a time t=0 the number I0 can be estimated a posteriori looking at epidemiological data for the next few days and depending on our estimate of β.
In order to estimate the parameters on the basis of the measurements of R, we can work either on R itself, or on its logarithm. That is, we have two alternative – but obviously equivalent – ways to proceed.
(a) Working on the time series for R(t).
We fit the time series around t0 by
R(t) = r0 + r1t + 12r2t2 ; | (2.24) |
Having these coefficients rk, we can compare with the series expansion for R(t) given by (2.22), which is just
R(t) = R0 + (βI0) t + 12(β2I0ϕ) t2 . | (2.25) |
We obtain easily that – using also the definition of ϕ (2.20) – our parameters and the associated parameter γ are given by
R0=r0 , I0 = r1β , ϕ = r2r1 β ;γ=βS0r1βr1+r2 . | (2.26) |
(b) Working on the time series for log[R(t)].
As R(t) grows – in the early phase – in a substantially (but not exactly, see above) exponential way, one usually deals with data in logarithmic form; that is one has a fit for log[R(t)], say of the form
log[R(t)] = A + Bt + 12C t2 . | (2.27) |
Comparing with the series expansion of log[R(t)] for R as in (2.22), i.e.,
log[R(t)]=log(R0) + β I0R0 t − 12 (βI0R0)2(1−ϕR0I0) t2 , | (2.28) |
we obtain that the I0, ϕ and γ parameters can be estimated as
R0=eA , I0 = Bβ eA , ϕ = B2 + 2Cβ B ;γ=βS0BβB+B2+2C . | (2.29) |
We stress again that our estimates for the parameters depend on our estimate for the leading parameter β.
This concludes our discussion of the standard SIR model.
It may happen to have an epidemic such that a rather large fraction of infected people are actually asymptomatic, but still fully infective; this appears to be the case for COVID-19. (albeit in the first stage it was believed that asymptomatic were not fully infectives, now they are thought to be so [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16].)
A little reflection shows that the presence of a large population of asymptomatic infectives, or however of infectives which show only very mild symptoms, easily thought not to be related with the concerned infective agent, changes the dynamics in two – contrasting – ways:
● On the one hand, asymptomatic infectives are a formidable vehicle of contagion, as they have no reason to take special precautions, and get in contact with a number of people which themselves do not take the due precautions (which would be taken in the case of an individual with evident symptoms);
● On the other hand, assuming once the infection is ceased the infected (including of course asymptomatic ones) have acquired permanent immunity, they contribute to group immunity reached once the population of susceptibles falls below the epidemic threshold.
We are thus going to study how the SIR dynamics is altered by the presence of a large class of asymptomatic infectives.
Remark 9. An obvious but important Remark is in order here. If we find out that known infectives are only a fraction ξ<1 of the total infectives, this means that on the one hand the mortality rate (number of deceased over number of infected) is actually smaller by the same factor. On the other hand, the total number of infected persons is increased by a factor ξ−1, so that it looks more difficult to stop the spreading of the epidemics, and the final number of infected will be quite large.
In this respect, one should however remember that the total number of casualties does not depend only on the total number of individuals with symptoms but also on the number of patients needing Intensive Care (for the COVID epidemic in China this was estimated at 20 % of hospitalized patients [41,42]; in Italy this fraction reached 10% at peak time, albeit in the most affected regions the number was higher [43,44,45]) and on the availability of such care; from this point of view, slowing down the pace of the epidemics can substantially lower the death toll even if the total number of affected individuals remains the same.
We will formulate a very simplified model of SIR type, where infective people are either symptomatic or asymptomatic. A more refined subdivision of their state would be more realistic, but the discussion of this simple case will suffice to show how to proceed in a more general setting.†
† A notable example of these more detailed models for COVID is provided by [46]. In our opinion keeping to a simple setting will help focusing on the essential mechanism at hand, albeit when facing a concrete epidemic the health authorities would probably prefer to follow a less generic model – if available, and if the available data are sufficient to reliably fit all the many parameters appearing in it.
In our model we still assume permanent immunity of individuals who have been infected and recovered, and constant population. We also assume that – as in the classical SIR – infected individuals are immediately infective (see Remark 1 in this regard). We will have susceptibles S(t) in a unique class, but two classes of infected and infective people: symptomatic I(t) and asymptomatic J(t); and similarly two classes of removed people: formerly symptomatic removed R(t) and formerly asymptomatic removed (mostly passing unnoticed through the infection) U(t). Symptomatic infectives are removed by the epidemic dynamics through isolation (in hospital or at home) at a removal rate β (thus with typical delay β−1, while asymptomatic people are removed from the epidemic dynamics mostly through spontaneous recovery, at a recovery rate η≪β, thus after a typical time η−1≫β−1; detecting asymptomatic infectives leads to their isolation before healing, and thus to a reduction in η−1.
We assume that both classes of infected people are infective in the same way, and that an individual who gets infected belongs with probability ξ to the class I and with probability (1−ξ) to the class J.
Our model, which we will call A-SIR (Asymptomatic-SIR) will then be
dS/dt=−α S(I+J)dI/dt=αξS(I+J) − βIdJ/dt=α(1−ξ)S(I+J) − ηJdR/dt=βIdU/dt=ηJ . | (3.1) |
Note that the last two equations amount to an integral, i.e., are solved by
R(t)=R0 + β ∫t0I(τ) dτ ,U(t)=U0 + η ∫t0J(τ) dτ ; | (3.2) |
thus they can be considered as "reconstruction equations", and we will focus on the first three equations in (3.1). Moreover, the total population N=S+I+J+R+U is constant.
Remark 10. The fact that asymptomatic infectives are as infective as symptomatic ones is not at all obvious. In the case of COVID-19 it appears we are in this situation [1,13,14,15]; in any case this will be our working hypothesis.
Remark 11. An alternative writing for the Eq (3.1) is also possible, and in some case convenient. We denote by
K(t) = I(t) + J(t) | (3.3) |
the total number of infectives, and by
x(t) = I(t)/K(t) | (3.4) |
the fraction of symptomatic infectives; obviously the fraction of asymptomatic ones will be y(t)=J(t)/K(t)=1−x(t).
By standard algebra the (first three) Eq (3.1) for the A-SIR dynamics are then rewritten in terms of these variables as
dS/dt=−αSKdK/dt=αSK − βx + η(1−x)Kdx/dt=αS(ξ−x) − (β−η)(1−x) . | (3.5) |
This writing also stresses that albeit ξ is a constant, the fraction x of symptomatic infectives is a dynamical variable.
Remark 12. We can now better discuss, in the light of the previous Remark 11, what are the intrinsic reasons which make that we expect the standard SIR model to perform poorly in describing an epidemic with a large number of asymptomatic infectives (see Remark 4 above). As already recalled, one would expect β to correspond to the inverse of the average removal time for registered infectives; however, once the presence of asymptomatic – and in particular undetected – infectives is ascertained, this could be corrected by accepting as β a weighted average B of the removal times for symptomatic and asymptomatic (that is, of β and η in the A-SIR model). But as we have just seen in Remark 11, the fraction x of symptomatic infectives is a dynamical variable, hence the parameter B should vary with time depending on the internal dynamics of the system (which is described by A-SIR, not by SIR), and hence we would be outside the proper SIR framework.
Some general considerations on Eq (3.1) can be made immediately. First of all, we note that I(t) will increase as far as the condition αξS(I+J)>βI is satisfied; that is, as far as
S > γ1 := 1ξ βα II+J = xξ βα . | (3.6) |
Thus the epidemic threshold (for symptomatic patients) γ1 depends both on the fixed parameters ξ,α,β and on the variable ratio x(t) of symptomatic infectives over total infectives, see (3.4).
Similarly, the number of asymptomatic infectives J(t) will grow as far as α(1−ξ)S(I+J)>ηJ is satisfied, i.e., as far as
S > γ2 := 11−ξ ηα JI+J = 1−x1−ξ ηα . | (3.7) |
Again the epidemic threshold (for asymptomatic patients) γ2 depends both on the fixed parameters ξ,α,η and on the variable ratio y(t)=1−x(t) of asymptomatic – and thus "hidden" – infectives over total infectives.
Note that
γ1γ2 = (1−ξξ) (βη) (IJ) = (1−ξξ) (βη) (x1−x) . |
As we expect on the one hand to have ξ<1/2 and β>η, but on the other hand I<J and hence x<1−x, we cannot claim there is a definite ordering between γ1 and γ2; this means that we will have situations where I declines and J is still growing, but the opposite is also possible.
We expect that in the very first phase –when the different removal times have not yet shown their effects – we have J≃[(1−ξ)/ξ]I and hence (1−x)≃[(1−ξ)/ξ]x; under this condition, we get
γ1γ2 ≃ βη > 1 . |
Remark 13. In the case of COVID-19, it is known that the incubation time is about 5.1 days; assuming that symptomatic infection is promptly recognized and swiftly treated, epidemiological and clinical data suggest the approximate values (note that asymptomatic removal time η−1 includes both the incubation time and the healing time) β−1≃5−7, η−1≃14−21 for the removal and recovery rates; the value of ξ is more controversial, as mentioned in the Introduction, but it is presently believed that ξ≃1/10. We will come back to these matters when dealing specifically with COVID, but wanted to give immediately an idea of what "realistic" values can be for the parameters appearing the A-SIR model.
It is quite clear that we can not go through the Kermack-McKendrick procedure to obtain approximate equations valid in the case of "small epidemics", not even through the simplified (first rather than second order) procedure we have used above. We can however go through the even simpler approach mentioned in Remark 8 (and which we have seen there produces the same results as the KMK procedure).
With S(t)≃S0, the equations (3.1) reduce to a linear system of four equations with constant coefficients, or more precisely to a "master" system of two equations
dIdt=(αξS0−β)I + (αξS0)J | (3.8) |
dJdt=[α(1−ξ)S0]I + [α(1−ξ)S0−η]J | (3.9) |
plus the two direct integrations (3.2). (note that if we use the alternative formulation (3.5), setting S≃S0 still leaves us with nonlinear equations.)
As for the two equations, (3.8) and (3.9), we can get their solution in explicit form by means of some standard algebra; they are slightly involved when written in fully explicit form, and we do not report them here.
With these, we can compute R(t) and U(t); their explicit expressions are also quite involved, and again we do not report them here.
Remark 14. As already remarked – and as well known from textbooks, see e.g., Murray [30] – we can only access R(t) from epidemiological data.In our case, this is the number of symptomatic patients which have been registered and thus isolated, i.e., in particular removed from the epidemic dynamic. As for U(t), this time series is basically unattainable: some of the asymptomatic infectives will be discovered and registered, but many – and probably most – of them will go unnoticed. Thus we should base our considerations only on R(t). Unfortunately, the data published by health agencies and by WHO do not distinguish between symptomatic and asymptomatic patients.
We can now proceed as in Section 2.5, i.e., series expand R(t) in order to fit the parameters. From the explicit expression of R(t) we get
R(t)≃R0 + βI0 t+12β[α(I0+J0)S0ξ−βI0] t2 ; | (3.10) |
log[R(t)]≃log(R0) + βI0R0 t+12 β[α(I0+J0)R0S0ξ− βI0(I0+R0)]R20 t2 . | (3.11) |
Comparing these with the generic form(which we repeat here for convenience of the reader: R(t)≃r0+r1t+(1/2)r2t2, log[R(t)]≃A+Bt+(1/2)Ct2.) of the fits (2.24) and (2.27), we can express the parameters I0 and γ=β/α. Note that we can not express both γ and J0 with the same fitting, as both of them only appear in the coefficient of the quadratic term. Note also that in this context γ is not any more the epidemic threshold, as discussed in Section 3.1; the time-varying epidemic threshold γ1(t)=[x(t)/ξ]γ is however expressed in terms of γ, so that it still makes sense to fit it.
Actually, since new infected are with probability ξ in the class I and with probability (1−ξ) in the class J, it is natural to set as initial condition
J0 = (1−ξξ) I0 ; | (3.12) |
with this assumption, we have
γ1(t0) = γ . | (3.13) |
Remark 15. It should be noted that actually if we want to fit γ we need to have some estimate on J0 (while I0 can be fitted from first order coefficient in the series for R(t) or log[R(t)]); to this aim we will use consistently (3.12).
In particular, using the fit of R we get (through this assumption)
R0 = r0 , I0 = r1β , γ = βr1S0(βr1 + r2) . | (3.14) |
Using instead the fit of log[R(t)], and again the assumption (3.12), we get
R0=eA , I0 = BeAβ ;γ=βS0BβB + B2 + 2C . | (3.15) |
Once the parameters are estimated, the nonlinear equations (3.1) can be solved numerically.
It is immediate to check that the expressions (3.14) and (3.15) – which we recall were obtained under the assumption (3.12) for J0 – are exactly the same as for the SIR model; see (2.26) and (2.29).
Summarizing our discussion so far, we have considered both the standard SIR model and a variant of it, the A-SIR model, taking into account the presence of large set of asymptomatic infectives. We have discussed in particular how the parameters for the models can be estimated on the basis of the time series for R(t) in the early stage of the epidemic.
We want now to discuss how the prediction extracted from a given time series for R(t) in the beginning of an epidemic differ if these are analyzed using the SIR or the A-SIR models.
As discussed above, we are able to extract only limited analytical information from the nonlinear SIR equations (2.1), and no relevant analytical predictions at all from the nonlinear A-SIR equations (3.1). Thus the only way to compare the predictions of the latter model with those of a standard SIR model (or variations on it, such as the SEIR model [30]), and hence see how the presence of a large class of asymptomatic infectives affects the dynamics within a SIR-type framework, is at present by running numerical simulations, i.e., numerically integrate the SIR and the A-SIR equations for coherent sets of parameters.
Here by "coherent" we will mean "extracted from the same time series for R(t) in the early phase of the epidemics".
In practice, in view of the discussion above and depending on our choice to use the (3.14) or the (3.15) fit, this means "with given {r0,r1,r2;β} or given {A,B,C;β} coefficients".
In the following, we will analyze the concrete epidemiological data for the COVID-19 epidemics in Italy, but here we would like to compare the SIR and the A-SIR predictions in a less concrete case, so that one can focus on general features rather than having a concrete case (with all the intricacies of real cases, see below) in mind.
We will thus choose an arbitrary (but realistic) set of parameters, which should be thought of as being extracted from the time series for the early phase of the epidemic. We consider a total population N=107, S0=N, and parameters
A = 5 , B = 0.1 , C = −0.002 ;β = 110 , η = 120 ; ξ = 110 . | (4.1) |
Moreover, we will assume that asymptomatic infectives (in the A-SIR modeling) are totally undetected; that is, we compare predictions which would be made by a mathematician using the SIR model and totally unaware of the existence of asymptomatic infectives with those made by a mathematician using the A-SIR model and aware of the relevance of asymptomatic infectives.
In Figure 2 we compare the predictions issued by the SIR and the A-SIR models for the cumulative number of (detected) removed, i.e., for R(t), and for the number of (detected, hence symptomatic) infectives I(t).
Note that not only the SIR predicts a higher infective peak, but it also expects it to occur at a later time; moreover for the initial phase, in particular after the A-SIR peak, the prediction of the number of infectives issued by the SIR model are lower than those issued by the A-SIR model. Note also that the SIR model expects a much greater part of the population to go through symptomatic infection, as seen from the R(t) plot.
These discrepancies are reduced, and somehow reversed, if in the A-SIR modeling we consider both symptomatic and asymptomatic infected. These graphs are plotted in Figure 3.
In a realistic situation one should expect that at least apart of the asymptomatic infectives are anyway detected (e.g., being tested due to contacts with known infectives). We have thus plotted the equivalent of Figure 3 in Figure 4, supposing that a fraction (1/5) of asymptomatic infectives is detected. Note that in this case the height of the epidemic peak is about the same as for the SIR model, but it occurs at an earlier time, while the number of detected removed when the epidemic is over is still substantially lower (about half) of the one predicted by the SIR model.
In other words, a modeler issuing his/her advice based on a SIR analysis in a situation where the A-SIR model applies, would make three substantial errors:
● The number of (symptomatic) infectives needing Hospital care would be over-estimated;
● The time before the epidemic peak – so the time available to prepare the health system to face it – would be over-estimated;
● The number of people not touched by the epidemic wave, so still in danger if a second wave arises, would be over-estimated.
It is rather clear that all of these errors would have substantial consequences. We stress that one could naively think that the presence of asymptomatic infections is essentially of help, in that a large part of the population getting in contact with the virus will not need any medical help. This is true, but on the other hand we have seen that it will also make that the curve raises more sharply than it would be expected on the basis of the SIR model (see also the discussion in Appendix A), and that in all the first phase of the epidemic – until the true epidemic peak and also for a period after this – the number of symptomatic infectives is higher than what would be foreseen in the basis of the SIR model.
We conclude that it is absolutely essential to take into account the presence of asymptomatic infectives.
In the previous Section 4 we have seen how the presence of asymptomatic infectives changes the predictions which would be done on the basis of the standard SIR model. In the present Section we want to consider a problem which naturally arises when consider an infection with a large number of asymptomatic infectives; that is, how the epidemiological dynamics is changed by an extensive campaign of testing (maybe tracing contacts of known infectives), followed of curse by treating – which in the case of asymptomatic means essentially just isolating the infectives so they they do not spread the infection.‡
‡ The title of the Section refers to the fortunate slogan proposed in the COVID-19 context. Much before this slogan was proposed, this approached was followed (in a low-tech mode) by the Padua group to tackle the COVID-19 epidemics in the field in Vò Euganeo and then in Veneto, with remarkable success [20].
To this aim, we will consider again – obviously just in the context of the A-SIR model – the situation seen in the previous Section, but will take into account the effects of such a "triple T" action by a reduction of the average removal time τ=η−1 for asymptomatic infectives. (A more detailed study is given in our related paper [47].)
We will thus run numerical simulations with the same parameters (except for η), total population and initial conditions as in Section 4 above, and choose three different values for η≤β, i.e., β=1/20,1/15,1/10. The result of these simulations is displayed in Figure 5.
We see from these that a "Tracing, Testing, Treating" campaign can reduce substantially the epidemic peak (more precisely, Figure 5 displays a reduction of the symptomatic epidemic peak – which is the relevant one in terms of charge on the health system – but the plot for the total infected would be analogous, except of course for a different scale.); on the other hand this leads to a slowing down of the epidemics, and to a smaller number of total infected individuals, i.e., to a smaller immune population at the end of the epidemic wave – and hence smaller resistance in the case of a second wave.
This concludes our general discussion. In the following, we will apply our formalism to the analysis of the COVID-19 epidemics in Italy.
In the previous sections, we have conducted our analysis in general terms. This referred to a generic infection with a large number of asymptomatic infectives, but of course the motivation for it was provided by the ongoing COVID-19 pandemic.
We will study in particular the situation in Italy; as well known, this was the first European country heavily struck by COVID, and data for it are widely available. Moreover, when COVID landed in Europe there was already an alert, so that transient phenomena due to late recognition of the problem – which were unavoidable in Eastern Asia – were of a much smaller size. Last but not least, in this case we are confident to have all the relevant information.
The data for the cumulative number of registered infected communicated by the Italian Health System [44] – and also available through the WHO reports [43] – are given in Table 1. There we give data for February 21 to May 15, albeit we will for the moment only use those for the first half of March; later data will be of use in the following. (We prefer not to use the data for the first few days, as too many spurious effects an affect these.)
day | Feb 21 | Feb 22 | Feb 23 | Feb 24 | Feb 25 |
R | 20 | 77 | 146 | 229 | 322 |
day | Feb 26 | Feb 27 | Feb 28 | Feb 29 | Mar 1 |
R | 400 | 650 | 888 | 1128 | 1694 |
day | Mar 2 | Mar 3 | Mar 4 | Mar 5 | Mar 6 |
R | 1835 | 2502 | 3089 | 3858 | 4636 |
day | Mar 7 | Mar 8 | Mar 9 | Mar 10 | Mar 11 |
R | 5883 | 7375 | 9172 | 10149 | 12462 |
day | Mar 12 | Mar 13 | Mar 14 | Mar 15 | Mar 16 |
R | 15113 | 17660 | 21157 | 24747 | 27980 |
day | Mar 17 | Mar 18 | Mar 19 | Mar 20 | Mar 21 |
R | 31506 | 35713 | 41035 | 47021 | 53578 |
day | Mar 22 | Mar 23 | Mar 24 | Mar 25 | Mar 26 |
R | 59138 | 63927 | 69176 | 74386 | 80539 |
day | Mar 27 | Mar 28 | Mar 29 | Mar 30 | Mar 31 |
R | 86498 | 92472 | 97689 | 101739 | 105792 |
day | Apr 1 | Apr 2 | Apr 3 | Apr 4 | Apr 5 |
R | 110574 | 115242 | 119827 | 124632 | 128948 |
day | Apr 6 | Apr 7 | Apr 8 | Apr 9 | Apr 10 |
R | 132547 | 135586 | 139422 | 143626 | 147577 |
day | Apr 11 | Apr 12 | Apr 13 | Apr 14 | Apr 15 |
R | 152271 | 156363 | 159516 | 162488 | 165155 |
day | Apr 16 | Apr 17 | Apr 18 | Apr 19 | Apr 20 |
R | 168941 | 172434 | 175925 | 178972 | 181228 |
day | Apr 21 | Apr 22 | Apr 23 | Apr 24 | Apr 25 |
R | 183957 | 187327 | 189973 | 192994 | 195351 |
day | Apr 26 | Apr 27 | Apr 28 | Apr 29 | Apr 30 |
R | 197675 | 199414 | 201505 | 203591 | 205463 |
day | May 1 | May 2 | May 3 | May 4 | May 5 |
R | 207428 | 209328 | 210717 | 211938 | 213013 |
day | May 6 | May 7 | May 8 | May 9 | May 10 |
R | 214457 | 215858 | 217185 | 218268 | 219070 |
day | May 11 | May 12 | May 13 | May 14 | May 15 |
R | 219814 | 221216 | 222104 | 223096 | 223885 |
One should note, in this respect, that the first cases in Italy (apart from sporadic and promptly isolated cases of tourists) were discovered on February 21. The public awareness campaign started immediately – and actually the public was already alert, e.g., it was impossible to find face masks since some weeks – and the first local mild restrictive measures were taken a few days later (February 24), and more restrictive measures involving the most affected areas (due to a leak of information, a number of people fled from the most affected area before the prohibition to do so went into effect; this has most probably pushed the spreading of the infection in different regions, but luckily the Southern regions, which were expected to be heavily affected by this, in the end were only marginally touched.) were taken on March 1. A more stringent set of measures went into effect for the whole nation on March 8, and still more strict measures on March 22.
Thus the epidemics developed with varying parameters. Moreover, as the incubation time for COVID ranges from 2 to 10 days, with a mean time of 5.1 days [21], there is a notable delay in the effect of any measure. Note that most countries have a quarantine length of 14 days; thus we expect that any measure will show their effect with a delay of one to two weeks.
For our fitting in the early phase, we will consider the data of the period March 1 through March 10, denoted in the following as ti and tf respectively; this leaves us some later days to compare the functions obtained through the fit with subsequent evolution, before the effect of the first set of measure can show up (March 15).
The best direct fit of R(t) through a quadratic function, see (2.24), is obtained with the constants
r0 = 3862.32 , r1 = 966.54 , r2 = 80.35 . | (6.1) |
The fit is reasonably good in the considered time interval (ti,tf), but fails completely for t<ti (see Figure 6, where we use data from February 24 on) and is rather poor for t>tf. This is not surprising, as we know that R(t) is, in this early phase, growing through a slightly corrected exponential law, see (2.22). (note however that here the fit has not the goal to provide an analytical description of R(t) for a larger interval of time, but only to estimate some parameters for the nonlinear SIR or A-SIR equations.)
Let us then look at the fit of log[R(t)] as in (2.27). In this case the best fit is obtained with the constants
A = 8.26648 , B = 0.221083 , C = −0.00430354 . | (6.2) |
In this case the fit is very good not only within (ti,tf) but also outside it, at least for the period until March 15. We will thus work only with this (exponential) fit.
We will consider these values for the coefficients {r0,r1,r2} or for the coefficients {A,B,C} as experimental measurements.
We can now use the formulas obtained before, both for the SIR and the A-SIR model, to estimate the parameters of these models in terms of these fits following the discussion in Sections 2.5 and 3.4.
We have remarked in Section 3.4 that the SIR and A-SIR models (in the latter case, under the assumption (3.12) for J0) yield exactly the same values for the I0 and γ parameters. Now we want to estimate these values for the data given in Section 6.2; this amounts to a direct application of formulas (3.14) and (3.15) – or equivalently (2.26) and (2.29), as already remarked.
As already remarked, these formulas depend on the estimated value of the parameter β. The values obtained using the direct fit of R are tabulated for different values of β in the upper part of Table 2.
QF | β | 1/3 | 1/4 | 1/5 | 1/6 | 1/7 | 1/8 | 1/9 | 1/10 |
I0 | 2900 | 3866 | 4833 | 5799 | 6766 | 7732 | 8699 | 9665 | |
ϕ | 0.25 | 0.33 | 0.42 | 0.50 | 0.58 | 0.67 | 0.75 | 0.83 | |
S0/γ | 1.25 | 1.33 | 1.42 | 1.50 | 1.58 | 1.67 | 1.75 | 1.83 | |
EF | β | 1/3 | 1/4 | 1/5 | 1/6 | 1/7 | 1/8 | 1/9 | 1/10 |
I0 | 2581 | 3441 | 4301 | 5162 | 6022 | 6882 | 7743 | 8602 | |
ϕ | 0.55 | 0.73 | 0.91 | 1.09 | 1.28 | 1.46 | 1.64 | 1.82 | |
S0/γ | 1.55 | 1.73 | 1.91 | 2.09 | 2.28 | 2.46 | 2.64 | 2.82 |
We can also proceed by using the fit of log[R(t)]; the values obtained in this way are tabulated for different values of β in the lower part of Table 2.
We remind that the delay time δ from infection to arise of symptoms is estimated to be around δ≃5.2 [21]; thus albeit we have tabulated several options for β, values greater than 1/5 are not realistic, at least in the absence of an agammaessive contact tracing and tracking campaign.
On the other hand, albeit we expect β−1 to be around one week for symptomatic patients, it should be recalled that in the standard SIR framework this parameter refers to the average removal time for all patients, symptomatic and asymptomatic. Thus the presence of asymptomatic ones could make β−1 to be substantially larger. We will leave this remark aside for the time being; see the discussion in the Appendix, in particular Remark A1.
In all cases, S0/γ is quite far from one and ϕ from zero, so one can not rely on the "small epidemic" formulas [30] discussed in Section 2.3. We will thus resort to numerical integration, see next Section.
This concludes our estimation of the SIR or A-SIR parameters from the epidemiological data referring to the early phase of the epidemic.
We have now determined the parameters for both the SIR and the A-SIR model in the very early phase of the epidemic; this determination depends actually on the value of β, so from now on we will consider β as the only parameter to be fitted.
We can now run numerical simulations with the SIR and the A-SIR equations; we can vary β (and thus implicitly also the other parameters, maintaining the relation between these and β) and fit β according to the agreement between the outcome of the numerical simulations and the epidemiological data.
In all of our simulations, day one is February 21, so the fitting period (ti,tf) corresponding to the first decade of March used to determine the relation between β and the other parameters is centered around day 14; but this does not determine β itself. We will now examine the fit of data in the first period outside this window in order to determine β.
Note that while the discussion of the previous Section 6 is complete for what concerns the SIR parameters, in the A-SIR equation we also need to introduce the removal rate for asymptomatic individuals, i.e., η; this is related to the time length δ=η−1 of their infective period, which is equal to the incubation time plus the spontaneous healing time§. While the former is around δ≃5, the latter is generally considered to be around 14 days, albeit we know that for hospitalized patients (which however are by definition symptomatic) this may be longer. Thus, on these medical grounds, we expect η−1 to be between 14 and 21 days.
§ More precisely, this would be the time until the viral load becomes too low to infect other individuals. From this point of view, different attitudes exist in different countries, also concerning isolation requirements. E.g., in Italy patients who tested positive but with little or light symptoms and are thus isolated at their home, are required to remain isolated until testing negative in two swab tests, while in Germany and other countries, they are automatically authorized to leave home after 14 days.
We ran a number of simulations, both for the SIR and the A-SIR dynamics, with varying β and – for the A-SIR model – with varying η; the parameter β was varied in the range (1/10−1/5), while η in the range (1/25,1/10).
The best results in terms of agreement with epidemiological data for the period March 1 through March 15 were obtained for
β = 17 , η = 121 . |
The plot for these values of the parameters are displayed in Figs. 7 and 8; note that for the SIR case the fit is rather poor.
In fact, it should be stressed that the situation is quite different in the cases of SIR and of A-SIR dynamics. In particular, the SIR dynamics does not fit the data for the week after the fitting window, while the A-SIR dynamics fits these quite well.
We stress that the fit β≃1/7 is coherent with medical data: In fact, as already recalled, the average delay from infection to the first symptoms is about 5 days, and there should be some further delay for recognizing these symptoms – which in the first phase can be rather trivial, such as cold, cough, or light fever – as due to COVID and leading to hospitalization or anyway to isolation.(this even disregarding the fact that at the peak of the epidemic the medical system was completely overwhelmed in several Departments – especially in Lombardia – and action was delayed.)
Remark 16. A relevant point should be made here. In the first phase of the epidemic, and in particular in the period covered by Figures 7 and 8, the COVID diffusion was essentially limited to Northern Italy, and in particular to the three regions of Lombardia, Veneto and Emilia-Romagna; the total population of Italy is about 60 millions, while that of the three mentioned regions totals about 20 millions. This is why simulations with both S0=2∗107 and S0=6∗107 are shown in these Figures. Actually, the comparison with the epidemiological data in the early stage should be better done with the simulation with S0=2∗107 (we are giving the other one for the SIR model only to show that even considering the overall population we do not get a reasonable fit).
In Section 4 above we have discussed the different timescale of an epidemic with given initial time series predicted by the SIR and by the A-SIR models. It is natural to wonder how long the COVID epidemic will last according to these.
This is not a well posed question, because there are restrictive measures being taken (or relaxed at a later stage, when the situation improves) which reduce the contact rate and thus the spread of the epidemic.
So, these simulations can at their best show what would be the behavior (of the system described by the SIR or A-SIR equations, which do not necessarily describe correctly the COVID epidemics) with constant coefficients. On the other hand, they can give an idea of what should be expected in case of no action.
More generally, and in line with our general discussion of Sections 4 and 5, they show how the dynamics predicted by the SIR and the A-SIR models with coherent sets of parameters differ from each other in general (albeit using the concrete COVID parameters to fix ideas).
It should be stressed in this context that the containment measures based on social distancing do not act on β, but on α; albeit in general α=β/γ, in studying the effect of restrictive measures it is more convenient to consider the reduction factor r. That is, if the fit of the initial phase of the epidemic yields α0=β0/γ0 (where γ0 is determined through the formulas of Sections 2.5 and 3.4), we consider in later phases a contact rate
α = r α0 , 0<r<1 . | (7.1) |
We will see that after the first set of measures in Italy we got r≃0.5 (compared with the initial period of the epidemic [48,49]), and after the second set of measures this went to r≃0.2, and to r≃0.08 at a still later stage.
Remark 17. It should be noted however that the studies suggesting the presence of a very large fraction of undetected infections [24] are also implicitly suggesting that the reduction in the epidemic growth could be due not only – or not so much – to the containment measures, but rather to the intrinsic dynamics of the system, and on the rapid depletion of the susceptibles reservoir. This point should be carefully considered. We find that in the case of COVID-19 in Italy our model suggests ξ=0.1, and discuss this point in view of that estimate. In order to fully explain the decrease of the contact rate by this mechanism – thus essentially to the often mentioned "herd immunity" – however, one would need ξ≃0.01, which appears to be non realistic (on the other hand, the suggestion ξ=0.02 [25] is still very low but cannot be discarded apriori).
Remark 18. The effect of different types of measures, let us say those acting on social distance and hence on α on the one hand, and those acting on early isolation and hence on β (and on η for the A-SIR model) on the other hand, on the epidemic timescale is specially relevant in view of the economic and social costs of a generalized lockdown as the one adopted in many European countries. This is discussed in detail in related publications [50,51,52], both for the SIR and the A-SIR models.
However, the real concrete interest of this study is in a different point. That is, there is considerable debate on the most appropriate way to use laboratory exams, and in particular if there should be a generalized COVID testing, at least of those having had contacts with known infects, or if only clinically suspect cases should be tested. We are of course aware that the real obstacle to a generalized testing – which should however be repeated over and over to be sure the individual has not been infected since the last test – is of practical nature, as testing a population of several tens of million people (not to say about China or India) is unfeasible, so that this alternative is a concrete one only in small communities; these could be isolated areas or also e.g., the community of people working in a Hospital. (we recall anyway that when this was conducted in the small community of Vo' Euganeo, the study led to a change in our basic understanding of the COVID spreading [20].)
On the other hand, a strategy aiming at generalized testing of those who have been in contact with known infectives is more feasible; actually this strategy was conducted with remarkable success in at least one Italian region, i.e., Veneto.
In any case, we want to study what the impact of reducing τ=η−1, thus raising η, would be on the development of the A-SIR dynamics. This is illustrated in Tables 3 and 4 below.
r | I∗ | t∗ | R∞/S0 | U∞/S0 | S∞/S0 | |
ξ=1/10 | 1.0 | 1.3∗106 | 57 | 0.10 | 0.89 | 0.01 |
η=1/21 | 0.8 | 1.0∗106 | 70 | 0.10 | 0.87 | 0.03 |
0.6 | 6.5∗105 | 95 | 0.09 | 0.82 | 0.09 | |
0.4 | 2.5∗105 | 167 | 0.07 | 0.65 | 0.28 |
r | te | R∞/S0 | U∞/S0 | |
ξ=1/10 | 0.2 | 539 | 1.02∗10−4 | 9.17∗10−3 |
η=1/21 | 0.1 | 107 | 2.67∗10−4 | 2.40∗10−3 |
0.05 | 66 | 2.09∗10−4 | 1.88∗10−3 | |
0.02 | 50 | 1.88∗10−4 | 1.69∗10−3 | |
0.01 | 46 | 1.82∗10−4 | 1.64∗10−3 |
As mentioned above, our numerical simulations suggest that the epidemic in Northern Italy is – or more precisely, was before the restrictive measures of March 8 went into operation – better described, in terms of our model, by the situation with
β=1/7 , η=1/21 ; ξ=1/10 . | (7.2) |
We will thus devote further analysis to this setting.(we have also conducted a detailed study of the case ξ=1/7, as suggested by Li et al. [23]; but the agreement with epidemiological data is definitely less good than for ξ=1/10 and hence these simulations will not be shown.)
When discussing if and how we can change these parameters, it is essential to state clearly what the two classes I and J (and hence also R and U) represent when we act on the system.
What we mean here is that in the "natural" situations J represents the class of asymptomatic and hence undetected infectives¶; on the other hand, when we start chasing for asymptomatic infectives these two characteristics are not equivalent.
¶ This was in particular true at the beginning of the COVID epidemic in Italy, when the amplitude of the asymptomatic infections was not realized; in fact, the WHO report on China was not alerting about the relevance of the phenomenon, and this was realized only after the study of the Padua group [20]. See also [1,4,8,9,10,13]
Here we will understand that J represents asymptomatic infectives, detected or undetected as they are.
It should be stressed that – at least in this framework, see below – these parameters cannot be altered: indeed, ξ depends on the interaction of the virus with human bodies and is thus fixed by Nature, while the removal time β−1≃7 can hardly be compressed considering that typically the first symptoms arise after 5 days, but these are usually weak and thus receive attention (especially in a difficult situation like the present one) only after some time.
Remark 19. We said above that the parameters β and ξ can not be altered "in this framework"; this requires a brief explanation. As for ξ this statement is rather clear||, and is connected to considering J as the class of asymptomatic infectives, while if they were meant to be the class of registered infectives, ξ could be altered by a large scale campaign of tests on asymptomatic population. On the other hand, for what concerns β the impossibility of compressing the time from infection to isolation is "in this framework" in the sense that in it isolation depends on the display of symptoms (plus some unavoidable reaction delay). The time δ=β−1 could instead be compressed by a campaign of tracing contacts of known (symptomatic or asymptomatic) infectives, as done in the field at Vò Euganeo [20]. These points will not be discussed here, but will be considered in a related paper [47].
|| It could depend on genetics, and thus differ in different continents, but for a given country it cannot be altered, as far as we know at the moment. Needless to say, if a medical treatment preventing the insurgence of symptom would become available, it would alter ξ but at the same time it would to a great extent solve the COVID problem.
On the other hand, it is conceivable that τ=η−1 could somehow be compressed if a general screening was conducted. At the same time, the contact rate α can be reduced by a more or less rigorous lockdown; in our discussion, this reduction is encoded in the reduction parameter r, which yields the ratio of the achieved contact rate over the "natural" one – i.e., the one measured at the beginning of the epidemic.
We have thus ran several numerical simulations for these values of β and ξ, both for a total population of N=2∗107 (the total population of the initially most affected regions) and for N=6∗107 (the total population of Italy).
These give of course very similar results – if referred to the total population – as our estimates for the parameters, and in particular for the one leading the dynamics, i.e., γ, depend themselves on S0.
Moreover, the questions discussed in this subsection do not concern the early phase of the epidemics (which was then limited to Northern Italy), but its future development. We will thus present the results directly for the case N=S0=6∗107.
We have investigated two questions:
(A) How a reduction in the removal time for asymptomatic infectives, i.e., in τ=η−1, would affect – according to the A-SIR model – the dynamics and the basic epidemiological outcomes of it in the regime where the epidemic is taking place;
(B) In the case r is small enough to make the population below the epidemic threshold, what are the basic epidemiological outcomes predicted by the model, again depending on various parameters including η.
The results of these numerical investigations are summarized in Tables 3 and 4 respectively. We have also studied, for comparison, question (B) in the framework of the standard SIR model (question (A) can not be set in this framework). The outcomes of this study are summarized in Table 5.
r | te | R∞/S0 | r | te | R∞/S0 |
0.20 | 57 | 2.29∗10−4 | 0.20 | 41 | 1.77∗10−4 |
0.10 | 49 | 1.98∗10−4 | 0.10 | 37 | 1.58∗10−4 |
0.05 | 46 | 1.87∗10−4 | 0.05 | 35 | 1.51∗10−4 |
0.02 | 44 | 1.81∗10−4 | 0.02 | 34 | 1.47∗10−4 |
0.01 | 44 | 1.79∗10−4 | 0.01 | 34 | 1.46∗10−4 |
These Tables show that a reduction of τ=η−1 can have a significant impact – more or less relevant depending on the r parameter – in the main epidemiological parameters, such as the infection peak, the epidemic time-span, and the fraction of the population which goes through infection with or without symptoms. (These results should be seen as preliminary, see the companion paper [47] for a more detailed study.)
The point we want to stress here is that even in this concrete case the predictions of the A-SIR model, taking into account the presence of a large set of asymptomatic infectives, differ from those of the standard SIR model; this difference is in some cases quite significant.
Remark 20. As mentioned above, these results are not a forecast of the development of the COVID epidemics, as they are obtained under the hypothesis of constant parameters, while political action will drive modification of the effective parameters in one way or the other.
Our study in the previous Sections went until March 17 (see Figures 7 and 8); this is the time interval in which it makes sense to consider constant parameters, as the first set of governmental measures did not show its effect yet, and we got a good fit of epidemiological data by our A-SIR model.
After (or shortly before) this date, the first set of restrictive measures, taken on March 8 and gradually enforced, should have shown their effect; thus – in terms of the model – the parameter α=α0 changed to a different value α=α1=r1α0. Similarly, more restrictive measures took effect on March 23 (this time in a sharper way), and this should have shown their effect about one week later, thus changing again the parameter α, say taking it to be α=α2=r2α0. It should be mentioned that albeit no official change took place, it was generally remarked that a different attitude in enforcing the measures appeared after Easter (April 11); at about the same time individual protective device became easily available. These changes are somehow reflected in our fitting, see below, by the introduction of a different reduction parameter r3 after April 25.
Thus in considering if our model can describe the actual development of the epidemic in Italy, one should take into account these changes of parameters, i.e., fit also the constants r1, r2 and r3 introduced above. It should be stressed that we do not have an analytical formula involving some parameters which can then be fitted against experimental data; we are instead studying numerical solution of the A-SIR dynamical system (3.1) and checking how this fits the data. On the other hand, we are assuming that nothing changes for the β, η and ξ parameters.
Data until May 15 are given in Table 1. We found a good agreement keeping the value ξ=1/10, and setting
r1 = 0.50 , r2 = 0.20 , r3 = 0.08 . | (8.1) |
In other words, we have set (recall time is measured in days, day 1 being February 21)
α = α(t) = {1.00∗α0t ≤ 25 ,0.50∗α025<t≤35 ,0.20∗α035<t≤63 ,0.08∗α063<t . | (8.2) |
Remark 21. Not that here we are considering the full Italian population, i.e., S0=6∗107; this introduces a factor 3 compared with the setting used in Sections 6 and 7 to fit α0 on the basis of the early data which concerned essentially three regions with a total population of about 2∗107; we have correspondingly to divide the α0 determined in there by a factor three, thus getting the value
α0 = 3.77∗10−9 ; | (8.3) |
this is to be used in (8.2) above.
Proceeding in this way, we obtain the curve plotted in Figure 9 against the epidemiological data; this curve shows a good agreement with the data. See also Figure 10 for a different representation in terms of the infectives I(t) (in one of the panels we have adopted a smoothing procedure consisting in mobile average over five days).
We give here a brief discussion of several aspects of the application of our theory to the specific situation of the COVID-19 epidemics in Italy, and of the results obtained above. This also involve non-mathematical matters. Moreover, the points touched upon here are not applying to the general theory, so we have preferred to keep this discussion separate from the short general one given in the next Section 9.
First of all, we note that the model allows to give an estimate also for the lockdown duration (assuming no further measures or relaxation of measures is adopted in the meanwhile, which is of course improbable in practical terms). E.g., if the lockdown should go on until the level of registered infectives present when the first measures were adopted on day 17, i.e., I(t)≃7,000, then according to the model and disregarding the third reduction, it should have gone on until day 129, i.e., the end of June. Taking into account also the third reduction in α, it should have gone until day 79, so May 19, in quite good agreement with the actual choice of the Italian Government to reduce limitations starting on May 18. We stress that according to our model and more generally to SIR-type models, a strategy based also on tracing contacts and early detection is much more effective (also in stopping the epidemic, as shown in the field by the Padua team [20], besides in keeping restrictions within an affordable time), as discussed in a companion paper [47]; see also [50,51,52].
Estimating the number of asymptomatic infectives is of course relevant in choosing measures to counteract the COVID-19 epidemics; as far as we know this is the first estimate based on a theoretical model and not just on statistical considerations. It follows from our model that the fraction x of symptomatic infectives – and the fraction y=1−x of asymptomatic ones – are dynamical variables, and change with time depending on other features of the system, in particular its total population. Thus a purely statistical evaluation appears to be necessarily misleading. See also Figure 11 in this regard.
The previous observation is specially significant when we look at the tail of the epidemic. In fact, while in this limit the ratio of removed infectives U(t)/R(t) goes to the natural limit (1−ξ)/ξ, the ratio of active infectives J(t)/I(t) goes to a much larger number, see Figure 11. This means that when restrictions are removed, it is absolutely essential to be able to track asymptomatic infectives, to avoid these can spark new fires of infection.
It should also be mentioned that our analysis suggests that the restrictive measures adopted in Italy were quite successful in reducing the contact rate α. This is in a way surprising, given their mild nature if compared to those adopted in China. A couple of facts should be recalled in this respect: (a) on the one hand a large part (possibly larger than in other European countries with a similar demographic profile) of infections and casualties is related to hospitals or senior citizens residences, so that once these were put under control the transmission rate was substantially lowered; the latter are much more common in the Northern regions; (b) a reduction on α has an impact on the (only) quadratic term in the SIR or A-SIR equations; thus a reduction in mobility by a factor μ could result in a reduction by a factor μ2 for the contact rate α.**
** In this respect, it should be mentioned that Google has provided data analyzing the reduction of mobility in different contexts for different countries [53]. These are difficult to compare across countries, as the restrictions have not been the same in different countries; there is however a homogeneous sector, as in all countries the access to food and medicine shops remained unrestricted. In these sector, according to the Google data for March, Italy is – among the large European countries severely affected by COVID – the one where the reduction in this sector was more marked. We have indeed -85% for Italy, -76% for Spain, -62% for France, -51% for Germany, - 46% for Great Britain. Thus the reduction of α could be not only, or not so much, due to the governmental measures, but to the more prudent attitude of citizens.
Finally, we note that while the first two steps in the α reduction are temporally correlated to the restrictive measures adopted by the Government and are thus thought to be due to these, the third step cannot be explained in such a way; several tentative explanations can be put forward (but with available data not scientifically tested) for this. These include relaxation of "stay at home" campaign (home is second only to senior citizens residence for frequency of contagion), availability and thus generalized use of individual protection device, increased solar UV radiation, and reduction of ambient viral load [54]. No final word on this matter can of course be said in terms of mathematical models alone.
Motivated by the peculiar features of the COVID epidemics, we have considered a SIR-type model, called A-SIR model, taking into account the presence of a large set of asymptomatic infectives.
We have shown that the dynamics of the SIR and the A-SIR models, for parameters fitted from the same set of data available in the early phase of an epidemic, differ significantly; this is not surprising, but is in itself a significant conclusion when we have to deal with a concrete epidemics with this characteristic. This is our first result.
We have analyzed the available data for the COVID-19 epidemics in Northern Italy in terms of the SIR and of the A-SIR models; in particular we have fitted the model parameters based on the period 1–10 March, and considered how these models with such parameters are performing in predicting the evolution for the subsequent week, 11–17 March. As shown by Figure 7 on the one hand, and by Figure 8 on the other hand, it appears that the A-SIR model is much better in predicting such (admittedly short time) evolution. In particular, this is the case with the estimate ξ=1/10 for the ratio of clearly symptomatic versus total infections (this is slightly smaller that the Li et al. [23] estimate ξ=1/7); and with the reasonable estimates β−1=7 days for the time from infection to isolation for symptomatic infectives, and η−1=21 for the time from infection to healing of asymptomatic infectives.
We have studied in more detail the case which best fits the epidemiological data outside the period used to fix the model parameters. This study was conducted in two directions.
(A) On the one hand, we have considered what would be the effect of a reduction of the time spent by asymptomatic being infective and non-isolated. In this framework, two cases are possible: either the restrictive measures are only mitigating the epidemic, or they are capable of stopping it by raising the epidemic threshold above the population level. In the first case, a reduction of η−1 from 21 to 14 days produce a substantial lowering of the epidemic peak and also substantially postpones its occurrence; in the second case, the effect of such a reduction may be quite relevant if the population remains just under the threshold (see the case with r=0.2 in Tables 4), or not so relevant if the reduction of the contact rate is taking the epidemic threshold well above the population level (see the cases with lower r in Table 4).
In all cases, there is a marked difference with the behavior of a standard SIR model with equivalent parameters.
(B) On the other hand, we have then considered how our model can describe the COVID-19 epidemic dynamic in Italy outside the time window used to fit the parameters. In this context, restrictive measures adopted in different stages have reduced the epidemic development, hence also altered the parameters – in particular, as the measures were essentially based on social distancing, the contact rate α. We have seen that assuming the measures showed their effect after one week (in line with our estimate β−1≃7) there is an estimate of their effect on the contact rate α which produces a good agreement between the model and the data.
This agreement depends on the chosen value for ξ, i.e., the ratio between symptomatic infections and total infections, and is quite good for ξ≃1/10 (confirming the early estimate by Vallance and Whitty [22]). It was stressed that this estimate of ξ is not of statistical nature, but follows instead from a theoretical model; this is specially relevant in that the same model shows that albeit the probability of symptomatic infection ξ is a constant, the different times for which symptomatic and asymptomatic infectives do take part in the epidemic dynamic makes that the fraction x of symptomatic over total infectives is a dynamical variable, and changes – even substantially – with time.††
†† In this respect, it should be mentioned that recently several Groups have suggested the fraction of detected infectives could be, for COVID, even smaller [24,25]; this would by all means make even greater the differences between the dynamic predictions by a standard SIR model or by a model, like the simple A-SIR model we propose here, taking into account the peculiar feature of the presence of a large class of asymptomatic infectives.
We trust that our work shows convincingly the need to take into account the presence of asymptomatic infectives – and the longer time they spend before going out of the infective dynamics – when they are a substantial number; see also the Appendix and [55].
The ongoing COVID-19 epidemic taught us that there can be relevant epidemics with a large number of asymptomatic infectives; more detailed models can surely be cast, but the very simple model presented here is already sufficient to show that the standard SIR model is not a good guide in this case, as it leads to overestimate certain very relevant parameters and underestimate others.
A more detailed study of how different strategies to mitigate the epidemic may affect the A-SIR dynamics is presented in a related paper [47]; see also [51,52].
I thank L. Peliti (SMRI), M. Cadoni (Cagliari) and E. Franco (Roma) for useful discussions. The paper was prepared over a (locked-in) stay at SMRI. The author is also a member of GNFM-INdAM.
The author declares no conflict of interest.
The basic reproduction number (BRN) is a popular indicator for the speed of diffusion of an epidemic in its first stages [38,39,40]. This is usually denoted as R0, but which here will be denoted as ρ0 (to avoid any confusion with the value of R(t) at t=0).
The BRN represents the average number of infections caused by a single infective; we want to discuss how the estimate of this can be flawed if one works with the SIR formalism in a situation where a large number of asymptomatic infectives is present, and hence better described by the A-SIR model; our discussion reproduces that in [55], and is given here for the sake of completeness.
The extraction of the BRN from epidemiological data can be tricky, but its evaluation in terms of a model is much simpler. In fact, in this case S(t) can be considered, for small t, as constant, i.e., S(t)≈S0. The SIR equations reduce to linear ones, and in the very beginning (before any infective can be removed) the new infectives grow as dI/dt=αS0I. Thus any infective produces αS0(δt) new infectives in a short time length δt. As each infective is active, on the average, for a time β−1, this yields a first rough estimate
ρ0 ≃ (α/β)S0 = S0/γ . | (A.1) |
Obviously, as β−1 is not so small (of the order of days), we should look more carefully at the equation for I(t), which can be solved and yields I(t)=exp[αS0t]I(0). As each infective is active for an average time δ=β−1, this just reads
I(δ) = exp[S0/ga] I(0) . | (A.2) |
The situation is slightly different if we take into account also the removal of infectives. With the same approximation SαpproxS0 but with the full (2.1) equations, we get dI/dt=α(S0−γ)I and hence
I(t) ≈ exp[α(S0−γ)t] I0 := H(t)I0 . |
Considering again that an infective remains active for a time δ=β−1 on average, the previous equation means that (on average) there will be ρ0=H(δ) new infectives originating from a single one. From the previous expression for H(t) we easily get ρ0=exp[(S0/γ)−1].
If we are facing a pathogen for which there is no natural immunity in the population (e.g., a new virus), S0=N (the total population) and we get
ρ0 = exp[Nγ − 1] . | (A.3) |
Thus, evaluating R0 is in this case immediate if we know γ; and conversely if we are able to evaluate ρ0 by epidemiological data, then it is immediate to evaluate γ as
γ = N1+log(ρ0) | (A.4) |
(or a simpler formula if we adopt the earlier and simpler definitions for ρ0, e.g., (A.1) above).
The parameter ρ0, and more generally ρ(t), met a great favor in the general press, as it gives the impression to describe a complex phenomenon by a single number. As we mentioned above, evaluating ρ(t) from epidemiological data can be a tricky matter [38,39], in particular if this is attempted without resorting to a specific model.
In this case too, using the SIR model without taking into account the presence of a large set of asymptomatic infectives leads to a wrong estimation of ρ, as we will see in a moment.
With the A-SIR equations (3.1), the number of new infected per unit of time is αS(I+J), and in the early phase of the epidemic we can assume S≈S0, and infectives will grow as
K(t+δt) = K(t) exp[α S0 δt] |
Thus each infective will give origin in the time span δt to exp[αS0δt] new infectives. In order to know the BRN, we should look at the average infective time τ in the early phase of the epidemic, and choose δt=τ. At the beginning of the epidemic the ratio between registered and total infectives is simply
x0 := I0I0+J0 ≃ ξ , | (A.5) |
while - as discussed above - in later stages the proportion between I and J changes, as individuals stay longer in the J class than in the I class.
The average removal rate for t≃0 is thus
B0 = ξβ + (1−ξ)η . | (A.6) |
This means that each (symptomatic or asymptomatic) infective individual will give direct origin, across its infective and non-isolation period, not to ρ0=exp[αS0/β]=exp[S0/γ] new infectives, but instead to
^ρ0 = exp[(α/B)S0] = (ρ0)β/B | (A.7) |
new infectives. As β>B, this means that the actual basic reproduction number ^ρ0 is larger - and possibly substantially larger - than the value ρ0 which would be estimated solely on the basis of registered infections.
A trivial computation on the basis of the values given above - i.e., β−1≃7, η−1≃21, ξ≃1/10 - provides
^ρ0 = (ρ0)5/2 . | (A.8) |
Recalling that the estimates of the COVID ρ0 on the basis of registered infectives are in the range ρ0∈(2.5−3.0), this means that the actual BRN turns out to be instead in the range
^ρ0 ∈ (10−15) . | (A.9) |
This could explain why all Health Systems were surprised by the rapid growth of the number of COVID-19 infections; in fact, the presence of a large set of asymptomatic infectives was not realized when the epidemic attacked the first countries, and is becoming clearly established only now.
Remark A.1. In terms of the standard SIR model, our discussion shows that one should consider B0 - see Eq (A.6) - rather than β in computing the BRN. This also explains the poor performance of the SIR model in fitting Italian epidemiological data with "medically reasonable" estimates for β; in fact, considering the B0 value instead of β produces a good enough fit [52]. See also Remark 12 in this context.
Remark A.2. On the other hand, it should be noted that according to Britton, Ball and Trapman [56] the herd immunity level for COVID-19 is substantially lower than the classical herd immunity level; this yields a nicer perspective for the future.
Remark A.3. Note that Eq (A.8) is obtained considering the A-SIR equivalent of Eq (A.4). Had we stayed with the rough estimate (A.1) (as in [55]), its A-SIR equivalent would have given ^ρ0=(5/2)ρ0, which means that the actual BRN is in the range ^ρ0∈(6.25−7.5), i.e., still substantially higher that the SIR estimation of ρ0.
[1] |
Corradin F, Billio M, Casarin R (2022) Forecasting Economic Indicators with Robust Factor Models. Natl Account Rev 4: 167–190. https://doi.org/10.3934/NAR.2022010 doi: 10.3934/NAR.2022010
![]() |
[2] |
Katusiime L (2023) COVID-19 and the effect of central bank intervention on exchange rate volatility in developing countries: The case of Uganda. Natl Account Rev 5: 23–37. https://doi.org/10.3934/NAR.2023002 doi: 10.3934/NAR.2023002
![]() |
[3] |
Mills TC (2022) Modelling the link between Covid-19 cases, hospital admissions and deaths in England. Natl Account Rev 4: 38–55. https://doi.org/10.3934/NAR.2022003 doi: 10.3934/NAR.2022003
![]() |
[4] |
Panarello D, Tassinari G (2022) The consequences of COVID-19 on older adults: evidence from the SHARE Corona Survey. Natl Account Rev 4: 56–73. https://doi.org/10.3934/NAR.2022004 doi: 10.3934/NAR.2022004
![]() |
[5] |
Zavras D (2022) Healthcare access as an important element for the EU's socioeconomic development: Greece's residents' opinions during the COVID-19 pandemic. Natl Account Rev 4: 362–377. https://doi.org/10.3934/NAR.2022020 doi: 10.3934/NAR.2022020
![]() |
1. | Hyun-Wook Lee, Sung-Hyun Park, Mao-wen Weng, Hsiang-Tsui Wang, William C. Huang, Herbert Lepor, Xue-Ru Wu, Lung-Chi Chen, Moon-shong Tang, E-cigarette smoke damages DNA and reduces repair activity in mouse lung, heart, and bladder as well as in human lung and bladder cells, 2018, 115, 0027-8424, 10.1073/pnas.1718185115 | |
2. | M. Boulanouar, O. Aouacheri, S. Saka, Potential Protective Effects of Turmeric (Curcuma longa) Supplementation on Cadmium-Induced Toxicity in Albinos Wistar Rat, 2023, 1624-8597, 10.3166/phyto-2022-0363 | |
3. | Daniel Andrew M. Gideon, Joel James, 2022, Chapter 185, 978-981-15-9410-6, 805, 10.1007/978-981-15-9411-3_185 | |
4. | Ashly Hindle, Sharda P. Singh, Jangampalli Adi Pradeepkiran, Chhanda Bose, Murali Vijayan, Sudhir Kshirsagar, Neha A. Sawant, P. Hemachandra Reddy, Rlip76: An Unexplored Player in Neurodegeneration and Alzheimer’s Disease?, 2022, 23, 1422-0067, 6098, 10.3390/ijms23116098 | |
5. | Francisco Bosch-Morell, Enrique García-Gen, Salvador Mérida, Mariola Penadés, Carmen Desco, Amparo Navea, Lipid Peroxidation in Subretinal Fluid: Some Light on the Prognosis Factors, 2021, 11, 2218-273X, 514, 10.3390/biom11040514 | |
6. | Livier Sánchez-Aceves, Itzayana Pérez-Alvarez, Leobardo Manuel Gómez-Oliván, Hariz Islas-Flores, Damià Barceló, Long-term exposure to environmentally relevant concentrations of ibuprofen and aluminum alters oxidative stress status on Danio rerio, 2021, 248, 15320456, 109071, 10.1016/j.cbpc.2021.109071 | |
7. | Rory P. Conolly, Harvey J. Clewell, Martha M. Moore, Jerry L. Campbell, Wanyun Cheng, R. Robinan Gentry, PBPK modeling to evaluate maximum tolerated doses: A case study with 3-chloroallyl alcohol, 2023, 14, 1663-9812, 10.3389/fphar.2023.1088011 | |
8. | Arash Rafeeinia, Gholamreza Asadikaram, Mehrnaz Karimi Darabi, Moslem Abolhassani, Vahid Moazed, Mojtaba Abbasi-Jorjandi, Organochlorine pesticides, oxidative stress biomarkers, and leukemia: a case–control study, 2023, 71, 1081-5589, 295, 10.1177/10815589221145043 | |
9. | Wen-hui Tao, Xi-sheng Shan, Jia-xin Zhang, Hua-yue Liu, Bi-ying Wang, Xiang Wei, Mian Zhang, Ke Peng, Jun Ding, Shang-xian Xu, Lin-gui Li, Jun-kai Hu, Xiao-wen Meng, Fu-hai Ji, Dexmedetomidine Attenuates Ferroptosis-Mediated Renal Ischemia/Reperfusion Injury and Inflammation by Inhibiting ACSL4 via α2-AR, 2022, 13, 1663-9812, 10.3389/fphar.2022.782466 | |
10. | Carla Iacobini, Martina Vitale, Jonida Haxhi, Carlo Pesce, Giuseppe Pugliese, Stefano Menini, Food-Related Carbonyl Stress in Cardiometabolic and Cancer Risk Linked to Unhealthy Modern Diet, 2022, 14, 2072-6643, 1061, 10.3390/nu14051061 | |
11. | Sabiha Fatima, Syed Shams Zaidi, Ashwag Saleh Alsharidah, Feda S. Aljaser, Naheed Banu, Possible Prophylactic Approach for SARS-CoV-2 Infection by Combination of Melatonin, Vitamin C and Zinc in Animals, 2020, 7, 2297-1769, 10.3389/fvets.2020.585789 | |
12. | Alessandra Peres, Igor M. Da Silva, Maeli Santos, Ângela Beretta, Vanessa Moraes Andrade, Pedro R. T. RomãO, Gilson P. Dorneles, DNA damage in mononuclear cells following maximal exercise in sedentary and physically active lean and obese men, 2021, 21, 1746-1391, 1073, 10.1080/17461391.2020.1801850 | |
13. | Meenakshi Bhardwaj, Padmavathy T.K., Sugumar Mani, Malarvizhi R, Veeresh Kumar Sali, Hannah R Vasanthi, Sulfated polysaccharide from Turbinaria ornata suppress lipopolysaccharide-induced inflammatory response in RAW 264.7 macrophages, 2020, 164, 01418130, 4299, 10.1016/j.ijbiomac.2020.09.036 | |
14. | Taye J. Lasisi, Shehu-Tijani T. Shittu, Jude I. Abeje, Kehinde J. Ogunremi, Seyyid A. Shittu, Paradoxical sleep deprivation induces oxidative stress in the submandibular glands of Wistar rats, 2022, 33, 0792-6855, 399, 10.1515/jbcpp-2020-0178 | |
15. | Alain Menzel, Hanen Samouda, Francois Dohet, Suva Loap, Mohammed S. Ellulu, Torsten Bohn, Common and Novel Markers for Measuring Inflammation and Oxidative Stress Ex Vivo in Research and Clinical Practice—Which to Use Regarding Disease Outcomes?, 2021, 10, 2076-3921, 414, 10.3390/antiox10030414 | |
16. | Ofem E. Eteng, Ceaser A. Moses, Emmanuel I. Ugwor, Joe E. Enobong, Adio J. Akamo, Dorcas I. Akinloye, Irene O. Sadiku, Arikpo Iwara, Eyong Ubana, Sub-acute exposure to Sudan IV-adulterated palm oil induces oxidative stress and represses the expression of Nrf2 and antioxidant genes in male albino rats, 2021, 39, 2689-6583, 400, 10.1080/26896583.2021.1965851 | |
17. | Paul R J Ames, Tommaso Bucci, Mira Merashli, Alessia Arcaro, Fabrizio Gentile, Thrombocytopaenia in antiphospholipid syndrome: a free radical perspective, 2022, 1462-0324, 10.1093/rheumatology/keac650 | |
18. | Masoud Soheili, Azam Alinaghipour, Mahmoud Salami, Good bacteria, oxidative stress and neurological disorders: Possible therapeutical considerations, 2022, 301, 00243205, 120605, 10.1016/j.lfs.2022.120605 | |
19. | Ninoslav Djelić, Sunčica Borozan, Vesna Dimitrijević-Srećković, Nevena Pajović, Milorad Mirilović, Helga Stopper, Zoran Stanimirović, Oxidative Stress and DNA Damage in Peripheral Blood Mononuclear Cells from Normal, Obese, Prediabetic and Diabetic Persons Exposed to Thyroid Hormone In Vitro, 2022, 23, 1422-0067, 9072, 10.3390/ijms23169072 | |
20. | Jan Spaas, Lieve van Veggel, Melissa Schepers, Assia Tiane, Jack van Horssen, David M. Wilson, Pablo R. Moya, Elisabeth Piccart, Niels Hellings, Bert O. Eijnde, Wim Derave, Rudy Schreiber, Tim Vanmierlo, Oxidative stress and impaired oligodendrocyte precursor cell differentiation in neurological disorders, 2021, 78, 1420-682X, 4615, 10.1007/s00018-021-03802-0 | |
21. | Debasish Basak, Mohammad Nasir Uddin, Jake Hancock, The Role of Oxidative Stress and Its Counteractive Utility in Colorectal Cancer (CRC), 2020, 12, 2072-6694, 3336, 10.3390/cancers12113336 | |
22. | Jaqueline Ferreira Campos, Helder Freitas dos Santos, Thaliny Bonamigo, Nelson Luís de Campos Domingues, Kely de Picoli Souza, Edson Lucas dos Santos, Cinzia Domenicotti, Stingless Bee Propolis: New Insights for Anticancer Drugs, 2021, 2021, 1942-0994, 1, 10.1155/2021/2169017 | |
23. | Arnold N. Onyango, Cellular Stresses and Stress Responses in the Pathogenesis of Insulin Resistance, 2018, 2018, 1942-0900, 1, 10.1155/2018/4321714 | |
24. | John Oludele Olanlokun, Mercy Toluwase Ekundayo, Neil Anthony Koorbanally, Olufunso Olabode Olorunsogo, Hexane fraction of Globimetula braunii induces mitochondria-mediated apoptosis in Plasmodium berghei-infected mice, 2022, 9, 22147500, 769, 10.1016/j.toxrep.2022.04.002 | |
25. | Călin Jianu, Laura-Cristina Rusu, Iulia Muntean, Ileana Cocan, Alexandra Teodora Lukinich-Gruia, Ionuț Goleț, Delia Horhat, Marius Mioc, Alexandra Mioc, Codruța Șoica, Gabriel Bujancă, Adrian Cosmin Ilie, Delia Muntean, In Vitro and In Silico Evaluation of the Antimicrobial and Antioxidant Potential of Thymus pulegioides Essential Oil, 2022, 11, 2076-3921, 2472, 10.3390/antiox11122472 | |
26. | Stefania Pizzimenti, Simone Ribero, Marie Angele Cucci, Margherita Grattarola, Chiara Monge, Chiara Dianzani, Giuseppina Barrera, Giuliana Muzio, Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies, 2021, 10, 2076-3921, 1942, 10.3390/antiox10121942 | |
27. | Hongyan Zhang, Yujiao Liu, Xuxiao Zong, Changcai Teng, Wanwei Hou, Ping Li, Dezhi Du, Genetic Diversity of Global Faba Bean Germplasm Resources Based on the 130K TNGS Genotyping Platform, 2023, 13, 2073-4395, 811, 10.3390/agronomy13030811 | |
28. | Noreddine Benkerroum, Chronic and Acute Toxicities of Aflatoxins: Mechanisms of Action, 2020, 17, 1660-4601, 423, 10.3390/ijerph17020423 | |
29. | Sangiliyandi Gurunathan, Muniyandi Jeyaraj, Min-Hee Kang, Jin-Hoi Kim, Anticancer Properties of Platinum Nanoparticles and Retinoic Acid: Combination Therapy for the Treatment of Human Neuroblastoma Cancer, 2020, 21, 1422-0067, 6792, 10.3390/ijms21186792 | |
30. | Yue Guo, Lei Wang, Andrea Hanson, Pedro E. Urriola, Gerald C. Shurson, Chi Chen, Identification of Protective Amino Acid Metabolism Events in Nursery Pigs Fed Thermally Oxidized Corn Oil, 2023, 13, 2218-1989, 103, 10.3390/metabo13010103 | |
31. | Stefano Menini, Carla Iacobini, Martina Vitale, Carlo Pesce, Giuseppe Pugliese, Diabetes and Pancreatic Cancer—A Dangerous Liaison Relying on Carbonyl Stress, 2021, 13, 2072-6694, 313, 10.3390/cancers13020313 | |
32. | Saurin R. Sutaria, Sadakatali S. Gori, James D. Morris, Zhenzhen Xie, Xiao-An Fu, Michael H. Nantz, Lipid Peroxidation Produces a Diverse Mixture of Saturated and Unsaturated Aldehydes in Exhaled Breath That Can Serve as Biomarkers of Lung Cancer—A Review, 2022, 12, 2218-1989, 561, 10.3390/metabo12060561 | |
33. | Amandine Moretton, Joanna I. Loizou, Interplay between Cellular Metabolism and the DNA Damage Response in Cancer, 2020, 12, 2072-6694, 2051, 10.3390/cancers12082051 | |
34. | Morana Jaganjac, Lidija Milkovic, Suzana Borovic Sunjic, Neven Zarkovic, The NRF2, Thioredoxin, and Glutathione System in Tumorigenesis and Anticancer Therapies, 2020, 9, 2076-3921, 1151, 10.3390/antiox9111151 | |
35. | Sungshim L. Park, Loic Le Marchand, Guang Cheng, Silvia Balbo, Menglan Chen, Steven G. Carmella, Nicole M. Thomson, Younghan Lee, Yesha M. Patel, Daniel O. Stram, Joni Jensen, Dorothy K. Hatsukami, Sharon E. Murphy, Stephen S. Hecht, Quantitation of DNA Adducts Resulting from Acrolein Exposure and Lipid Peroxidation in Oral Cells of Cigarette Smokers from Three Racial/Ethnic Groups with Differing Risks for Lung Cancer, 2022, 35, 0893-228X, 1914, 10.1021/acs.chemrestox.2c00171 | |
36. | Camille Audousset, Toby McGovern, James G. Martin, Role of Nrf2 in Disease: Novel Molecular Mechanisms and Therapeutic Approaches – Pulmonary Disease/Asthma, 2021, 12, 1664-042X, 10.3389/fphys.2021.727806 | |
37. | Andriy Cherkas, Neven Zarkovic, 4-Hydroxynonenal in Redox Homeostasis of Gastrointestinal Mucosa: Implications for the Stomach in Health and Diseases, 2018, 7, 2076-3921, 118, 10.3390/antiox7090118 | |
38. | Padmanabh Singh, Bhabotosh Barman, Mahendra Kumar Thakur, Oxidative stress-mediated memory impairment during aging and its therapeutic intervention by natural bioactive compounds, 2022, 14, 1663-4365, 10.3389/fnagi.2022.944697 | |
39. | Elena E. Pohl, Olga Jovanovic, The Role of Phosphatidylethanolamine Adducts in Modification of the Activity of Membrane Proteins under Oxidative Stress, 2019, 24, 1420-3049, 4545, 10.3390/molecules24244545 | |
40. | Daniel Andrew M. Gideon, Joel James, 2021, Chapter 185-1, 978-981-15-4501-6, 1, 10.1007/978-981-15-4501-6_185-1 | |
41. | Scott J. Walmsley, Jingshu Guo, Paari Murugan, Christopher J. Weight, Jinhua Wang, Peter W. Villalta, Robert J. Turesky, Comprehensive Analysis of DNA Adducts Using Data-Independent wSIM/MS2 Acquisition and wSIM-City, 2021, 93, 0003-2700, 6491, 10.1021/acs.analchem.1c00362 | |
42. | Shunji Kato, Naoki Shimizu, Yurika Otoki, Junya Ito, Masayoshi Sakaino, Takashi Sano, Shigeo Takeuchi, Jun Imagi, Kiyotaka Nakagawa, Determination of acrolein generation pathways from linoleic acid and linolenic acid: increment by photo irradiation, 2022, 6, 2396-8370, 10.1038/s41538-022-00138-2 | |
43. | Federica Papaccio, Andrea D′Arino, Silvia Caputo, Barbara Bellei, Focus on the Contribution of Oxidative Stress in Skin Aging, 2022, 11, 2076-3921, 1121, 10.3390/antiox11061121 | |
44. | Iliana Ivanova, Radostina Toshkovska, Lyubomira Yocheva, Dayana Benkova, Vesela Yordanova, Alexandrina Nesheva, Rusina Hazarosova, Galya Staneva, Aneliya Kostadinova, 2023, Chapter 15, 978-3-031-31068-3, 147, 10.1007/978-3-031-31069-0_15 | |
45. | Mohsen Sisakht, Maryam Darabian, Amir Mahmoodzadeh, Ali Bazi, Sayed Mohammad Shafiee, Pooneh Mokarram, Zahra Khoshdel, The role of radiation induced oxidative stress as a regulator of radio-adaptive responses, 2020, 96, 0955-3002, 561, 10.1080/09553002.2020.1721597 | |
46. | Agata Los, Dana Ziuzina, Robin Van Cleynenbreugel, Daniela Boehm, Paula Bourke, Assessing the Biological Safety of Atmospheric Cold Plasma Treated Wheat Using Cell and Insect Models, 2020, 9, 2304-8158, 898, 10.3390/foods9070898 | |
47. | Ariane Schröter, Hanns-Christian Mahler, Nadia Ben Sayed, Atanas V. Koulov, Jörg Huwyler, Michael Jahn, 4-Hydroxynonenal – A Toxic Leachable from Clinically Used Administration Materials, 2021, 110, 00223549, 3268, 10.1016/j.xphs.2021.05.014 | |
48. | Tauseef Alam, Sana Rizwan, Zeba Farooqui, Subuhi Abidi, Iqbal Parwez, Farah Khan, Oral Nigella sativa oil administration alleviates arsenic-induced redox imbalance, DNA damage, and metabolic and histological alterations in rat liver, 2021, 28, 0944-1344, 41464, 10.1007/s11356-021-13493-6 | |
49. | Reyhaneh Moradi‐Marjaneh, Seyed Mahdi Hassanian, Mehraneh Mehramiz, Majid Rezayi, Gordon A. Ferns, Majid Khazaei, Amir Avan, Reactive oxygen species in colorectal cancer: The therapeutic impact and its potential roles in tumor progression via perturbation of cellular and physiological dysregulated pathways, 2019, 234, 0021-9541, 10072, 10.1002/jcp.27881 | |
50. | Kun Lu, Yun-Chung Hsiao, Chih-Wei Liu, Rita Schoeny, Robinan Gentry, Thomas B. Starr, A Review of Stable Isotope Labeling and Mass Spectrometry Methods to Distinguish Exogenous from Endogenous DNA Adducts and Improve Dose–Response Assessments, 2022, 35, 0893-228X, 7, 10.1021/acs.chemrestox.1c00212 | |
51. | Alessandro Attanzio, Ignazio Restivo, Marco Tutone, Luisa Tesoriere, Mario Allegra, Maria A. Livrea, Redox Properties, Bioactivity and Health Effects of Indicaxanthin, a Bioavailable Phytochemical from Opuntia ficus indica, L.: A Critical Review of Accumulated Evidence and Perspectives, 2022, 11, 2076-3921, 2364, 10.3390/antiox11122364 | |
52. | Nadeem G Khan, Sangavi Eswaran, Divya Adiga, S. Sriharikrishnaa, Sanjiban Chakrabarty, Padmalatha S. Rai, Shama Prasada Kabekkodu, Integrated bioinformatic analysis to understand the association between phthalate exposure and breast cancer progression, 2022, 457, 0041008X, 116296, 10.1016/j.taap.2022.116296 | |
53. | Georg Wultsch, Tahereh Setayesh, Michael Kundi, Michael Kment, Armen Nersesyan, Michael Fenech, Siegfried Knasmüller, Induction of DNA damage as a consequence of occupational exposure to crystalline silica: A review and meta-analysis, 2021, 787, 13835742, 108349, 10.1016/j.mrrev.2020.108349 | |
54. | Caroline Molinaro, Alain Martoriati, Katia Cailliau, Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies, 2021, 13, 2072-6694, 3819, 10.3390/cancers13153819 | |
55. | Morana Jaganjac, Lidija Milkovic, Agnieszka Gegotek, Marina Cindric, Kamelija Zarkovic, Elzbieta Skrzydlewska, Neven Zarkovic, The relevance of pathophysiological alterations in redox signaling of 4-hydroxynonenal for pharmacological therapies of major stress-associated diseases, 2020, 157, 08915849, 128, 10.1016/j.freeradbiomed.2019.11.023 | |
56. | Jacob L. Brown, Fredrick F. Peelor, Constantin Georgescu, Jonathan D. Wren, Michael Kinter, Victoria J. Tyrrell, Valerie B. O'Donnell, Benjamin F. Miller, Holly Van Remmen, Lipid hydroperoxides and oxylipins are mediators of denervation induced muscle atrophy, 2022, 57, 22132317, 102518, 10.1016/j.redox.2022.102518 | |
57. | Ruofei Du, Li Luo, Laurie G. Hudson, Sara Nozadi, Johnnye Lewis, An adjusted partial least squares regression framework to utilize additional exposure information in environmental mixture data analysis, 2022, 0266-4763, 1, 10.1080/02664763.2022.2043254 | |
58. | Rory B Conolly, Jeffry Schroeter, Julia S Kimbell, Harvey Clewell, Melvin E Andersen, P Robinan Gentry, Updating the biologically based dose-response model for the nasal carcinogenicity of inhaled formaldehyde in the F344 rat, 2023, 193, 1096-6080, 1, 10.1093/toxsci/kfad028 | |
59. | Analía Alejandra Lu-Martínez, Juan Gabriel Báez-González, Sandra Castillo-Hernández, Carlos Amaya-Guerra, José Rodríguez-Rodríguez, Eristeo García-Márquez, Studied of Prunus serotine oil extracted by cold pressing and antioxidant effect of P. longiflora essential oil, 2021, 58, 0022-1155, 1420, 10.1007/s13197-020-04653-6 | |
60. | Agnieszka Gęgotek, Anna Jastrząb, Marta Dobrzyńska, Michał Biernacki, Elżbieta Skrzydlewska, Exogenous Antioxidants Impact on UV-Induced Changes in Membrane Phospholipids and the Effectiveness of the Endocannabinoid System in Human Skin Cells, 2021, 10, 2076-3921, 1260, 10.3390/antiox10081260 | |
61. | Robert Nilsson, Ning-Ang Liu, Nuclear DNA damages generated by reactive oxygen molecules (ROS) under oxidative stress and their relevance to human cancers, including ionizing radiation-induced neoplasia part I: Physical, chemical and molecular biology aspects, 2020, 1, 26665557, 140, 10.1016/j.radmp.2020.09.002 | |
62. | Ariane Schröter, Atanas V. Koulov, Jörg Huwyler, Hanns-Christian Mahler, Michael Jahn, 4-Hydroxynonenal is An Oxidative Degradation Product of Polysorbate 80, 2021, 110, 00223549, 2524, 10.1016/j.xphs.2021.01.027 | |
63. | Shimaa I. Rakha, Mohammed A. Elmetwally, Hossam El-Sheikh Ali, Ahmed Zaky Balboula, Abdelmonem Montaser Mahmoud, Samy M. Zaabel, Lycopene Reduces the In Vitro Aging Phenotypes of Mouse Oocytes by Improving Their Oxidative Status, 2022, 9, 2306-7381, 336, 10.3390/vetsci9070336 | |
64. | Rajesh Singh Jadon, Gajanand Sharma, Neeraj K. Garg, Nikunj Tandel, Kavita R. Gajbhiye, Rajesh Salve, Virendra Gajbhiye, Ujjawal Sharma, Om Prakash Katare, Manoj Sharma, Rajeev K. Tyagi, Efficient in vitro and in vivo docetaxel delivery mediated by pH-sensitive LPHNPs for effective breast cancer therapy, 2021, 203, 09277765, 111760, 10.1016/j.colsurfb.2021.111760 | |
65. | Koraljka Gall Trošelj, Marko Tomljanović, Morana Jaganjac, Tanja Matijević Glavan, Ana Čipak Gašparović, Lidija Milković, Suzana Borović Šunjić, Brigitta Buttari, Elisabetta Profumo, Sarmistha Saha, Luciano Saso, Neven Žarković, Oxidative Stress and Cancer Heterogeneity Orchestrate NRF2 Roles Relevant for Therapy Response, 2022, 27, 1420-3049, 1468, 10.3390/molecules27051468 | |
66. | Arash Rafeeinia, Gholamreza Asadikaram, Mehrnaz Karimi-Darabi, Moslem Abolhassani, Mojtaba Abbasi-Jorjandi, Vahid Moazed, Organochlorine Pesticides, Oxidative Stress Biomarkers, and Leukemia: A Case-Control Study, 2022, 70, 1081-5589, 1736, 10.1136/jim-2021-002289 | |
67. | Nouf M. Alyami, Rafa Almeer, Hanadi M. Alyami, Role of green synthesized platinum nanoparticles in cytotoxicity, oxidative stress, and apoptosis of human colon cancer cells (HCT-116), 2022, 8, 24058440, e11917, 10.1016/j.heliyon.2022.e11917 | |
68. | Jingshu Guo, Joseph S. Koopmeiners, Scott J. Walmsley, Peter W. Villalta, Lihua Yao, Paari Murugan, Resha Tejpaul, Christopher J. Weight, Robert J. Turesky, The Cooked Meat Carcinogen 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine Hair Dosimeter, DNA Adductomics Discovery, and Associations with Prostate Cancer Pathology Biomarkers, 2022, 35, 0893-228X, 703, 10.1021/acs.chemrestox.2c00012 | |
69. | Vladislav Vladimirovich Tsukanov, Olga Valentinovna Smirnova, Edward Vilyamovich Kasparov, Alexander Alexandrovich Sinyakov, Alexander Viktorovich Vasyutin, Julia Leongardovna Tonkikh, Mikhail Alexandrovich Cherepnin, Dynamics of Oxidative Stress in Helicobacter pylori-Positive Patients with Atrophic Body Gastritis and Various Stages of Gastric Cancer, 2022, 12, 2075-4418, 1203, 10.3390/diagnostics12051203 | |
70. | Hong-Min Qin, Denise Herrera, Dian-Feng Liu, Chao-Qian Chen, Armen Nersesyan, Miroslav Mišík, Siegfried Knasmueller, Genotoxic properties of materials used for endoprostheses: Experimental and human data, 2020, 145, 02786915, 111707, 10.1016/j.fct.2020.111707 | |
71. | Deema Islayem, Fatima Ba Fakih, Sungmun Lee, Comparison of Colorimetric Methods to Detect Malondialdehyde, A Biomarker of Reactive Oxygen Species, 2022, 7, 2365-6549, 10.1002/slct.202103627 | |
72. | Balázs Olasz, Béla Fiser, Milán Szőri, Béla Viskolcz, Michael C. Owen, Computational Elucidation of the Solvent-Dependent Addition of 4-Hydroxy-2-nonenal (HNE) to Cysteine and Cysteinate Residues, 2022, 87, 0022-3263, 12909, 10.1021/acs.joc.2c01487 | |
73. | Josh Williamson, Gareth Davison, Targeted Antioxidants in Exercise-Induced Mitochondrial Oxidative Stress: Emphasis on DNA Damage, 2020, 9, 2076-3921, 1142, 10.3390/antiox9111142 | |
74. | Eunnara Cho, Ashley Allemang, Marc Audebert, Vinita Chauhan, Stephen Dertinger, Giel Hendriks, Mirjam Luijten, Francesco Marchetti, Sheroy Minocherhomji, Stefan Pfuhler, Daniel J. Roberts, Kristina Trenz, Carole L. Yauk, AOP report: Development of an adverse outcome pathway for oxidative DNA damage leading to mutations and chromosomal aberrations , 2022, 63, 0893-6692, 118, 10.1002/em.22479 | |
75. | Ion Alexandru Bobulescu, Laurentiu M. Pop, Chinnadurai Mani, Kala Turner, Christian Rivera, Sabiha Khatoon, Subash Kairamkonda, Raquibul Hannan, Komaraiah Palle, Renal Lipid Metabolism Abnormalities in Obesity and Clear Cell Renal Cell Carcinoma, 2021, 11, 2218-1989, 608, 10.3390/metabo11090608 | |
76. | Sarmistha Saha, Luciano Saso, Guliz Armagan, Cancer Prevention and Therapy by Targeting Oxidative Stress Pathways, 2023, 28, 1420-3049, 4293, 10.3390/molecules28114293 | |
77. | Anna Chiaramonte, Serena Testi, Caterina Pelosini, Consuelo Micheli, Aurora Falaschi, Giovanni Ceccarini, Ferruccio Santini, Roberto Scarpato, Oxidative and DNA damage in obese patients undergoing bariatric surgery: a one-year follow-up study, 2023, 00275107, 111827, 10.1016/j.mrfmmm.2023.111827 | |
78. | Amelia Rojas‐Gómez, Sara G. Dosil, Francisco J. Chichón, Nieves Fernández‐Gallego, Alessia Ferrarini, Enrique Calvo, Diego Calzada‐Fraile, Silvia Requena, Joaquin Otón, Alvaro Serrano, Rocio Tarifa, Montserrat Arroyo, Andrea Sorrentino, Eva Pereiro, Jesus Vázquez, José M. Valpuesta, Francisco Sánchez‐Madrid, Noa B. Martín‐Cófreces, Chaperonin CCT controls extracellular vesicle production and cell metabolism through kinesin dynamics, 2023, 12, 2001-3078, 10.1002/jev2.12333 | |
79. | Yulemni Morel, Jace W. Jones, Utilization of LC–MS/MS and Drift Tube Ion Mobility for Characterizing Intact Oxidized Arachidonate-Containing Glycerophosphatidylethanolamine, 2023, 1044-0305, 10.1021/jasms.3c00083 | |
80. | Karoline Felisbino, Nathalia Kirsten, Shayane da Silva Milhorini, Isabela Saragioto Marçal, Karina Bernert, Rafaela Schiessl, Leticia Nominato-Oliveira, Izonete Cristina Guiloski, Teratogenic effects of the dicamba herbicide in Zebrafish (Danio rerio) embryos, 2023, 02697491, 122187, 10.1016/j.envpol.2023.122187 | |
81. | Renan Muniz-Santos, Giovanna Lucieri-Costa, Matheus Augusto P. de Almeida, Isabelle Moraes-de-Souza, Maria Alice Dos Santos Mascarenhas Brito, Adriana Ribeiro Silva, Cassiano Felippe Gonçalves-de-Albuquerque, Lipid oxidation dysregulation: an emerging player in the pathophysiology of sepsis, 2023, 14, 1664-3224, 10.3389/fimmu.2023.1224335 | |
82. | Adam Wroński, Izabela Dobrzyńska, Szymon Sękowski, Wojciech Łuczaj, Ewa Olchowik-Grabarek, Elżbieta Skrzydlewska, Cannabidiol and Cannabigerol Modify the Composition and Physicochemical Properties of Keratinocyte Membranes Exposed to UVA, 2023, 24, 1422-0067, 12424, 10.3390/ijms241512424 | |
83. | Tao Shen, Haiyang Wang, Rongkang Hu, Yanni Lv, Developing neural network diagnostic models and potential drugs based on novel identified immune-related biomarkers for celiac disease, 2023, 17, 1479-7364, 10.1186/s40246-023-00526-z | |
84. | Krystal D. Kao, Helmut Grasberger, Mohamad El-Zaatari, The Cxcr2+ subset of the S100a8+ gastric granylocytic myeloid-derived suppressor cell population (G-MDSC) regulates gastric pathology, 2023, 14, 1664-3224, 10.3389/fimmu.2023.1147695 | |
85. | Nurbubu T. Moldogazieva, Sergey P. Zavadskiy, Dmitry V. Astakhov, Alexander A. Terentiev, Lipid peroxidation: Reactive carbonyl species, protein/DNA adducts, and signaling switches in oxidative stress and cancer, 2023, 0006291X, 149167, 10.1016/j.bbrc.2023.149167 | |
86. | Rohit Sharma, Bhawna Diwan, Lipids and the hallmarks of ageing: From pathology to interventions, 2023, 215, 00476374, 111858, 10.1016/j.mad.2023.111858 | |
87. | Nahed Nasser Eid El-Sayed, Taghreed M. Al-Otaibi, Assem Barakat, Zainab M. Almarhoon, Mohd. Zaheen Hassan, Maha I. Al-Zaben, Najeh Krayem, Vijay H. Masand, Abir Ben Bacha, Synthesis and Biological Evaluation of Some New 3-Aryl-2-thioxo-2,3-dihydroquinazolin-4(1H)-ones and 3-Aryl-2-(benzylthio)quinazolin-4(3H)-ones as Antioxidants; COX-2, LDHA, α-Glucosidase and α-Amylase Inhibitors; and Anti-Colon Carcinoma and Apoptosis-Inducing Agents, 2023, 16, 1424-8247, 1392, 10.3390/ph16101392 | |
88. | Yangling Zhang, Yuxin Song, Jiao Zhang, Lanlan Li, Lin He, Jiahui Bo, Zhihua Gong, Wenjun Xiao, L-theanine regulates the immune function of SD rats fed high-protein diets through the FABP5/IL-6/STAT3/PPARα pathway, 2023, 181, 02786915, 114095, 10.1016/j.fct.2023.114095 | |
89. | Dessislava Staneva, Neli Dimitrova, Borislav Popov, Albena Alexandrova, Milena Georgieva, George Miloshev, Haberlea rhodopensis Extract Tunes the Cellular Response to Stress by Modulating DNA Damage, Redox Components, and Gene Expression, 2023, 24, 1422-0067, 15964, 10.3390/ijms242115964 | |
90. | Junying Yuan, Dimitry Ofengeim, A guide to cell death pathways, 2023, 1471-0072, 10.1038/s41580-023-00689-6 | |
91. | Agnieszka Gęgotek, Elżbieta Skrzydlewska, Lipid peroxidation products’ role in autophagy regulation, 2024, 212, 08915849, 375, 10.1016/j.freeradbiomed.2024.01.001 | |
92. | Liuling Xiao, Miao Xian, Chuanchao Zhang, Qi Guo, Qing Yi, Lipid peroxidation of immune cells in cancer, 2024, 14, 1664-3224, 10.3389/fimmu.2023.1322746 | |
93. | Oleg M. Panasenko, Yury A. Vladimirov, Valery I. Sergienko, Free Radical Lipid Peroxidation Induced by Reactive Halogen Species, 2024, 89, 0006-2979, S148, 10.1134/S0006297924140098 | |
94. | Sydney Bartman, Giuseppe Coppotelli, Jaime M. Ross, Mitochondrial Dysfunction: A Key Player in Brain Aging and Diseases, 2024, 46, 1467-3045, 1987, 10.3390/cimb46030130 | |
95. | Adnan Moinuddin, Sophie M. Poznanski, Ana L. Portillo, Jonathan K. Monteiro, Ali A. Ashkar, Metabolic adaptations determine whether natural killer cells fail or thrive within the tumor microenvironment, 2024, 0105-2896, 10.1111/imr.13316 | |
96. | Lindalva Maria de Meneses Costa Ferreira, Poliana Dimsan Queiroz de Souza, Rayanne Rocha Pereira, Edilene Oliveira da Silva, Wagner Luiz Ramos Barbosa, José Otávio Carréra Silva-Júnior, Attilio Converti, Roseane Maria Ribeiro-Costa, Preliminary Study on the Chemical and Biological Properties of Propolis Extract from Stingless Bees from the Northern Region of Brazil, 2024, 12, 2227-9717, 700, 10.3390/pr12040700 | |
97. | Francesca Pagliari, Jeannette Jansen, Jan Knoll, Rachel Hanley, Joao Seco, Luca Tirinato, Cancer radioresistance is characterized by a differential lipid droplet content along the cell cycle, 2024, 19, 1747-1028, 10.1186/s13008-024-00116-y | |
98. | Alessandro Vacchini, Andrew Chancellor, Qinmei Yang, Rodrigo Colombo, Julian Spagnuolo, Giuliano Berloffa, Daniel Joss, Ove Øyås, Chiara Lecchi, Giulia De Simone, Aisha Beshirova, Vladimir Nosi, José Pedro Loureiro, Aurelia Morabito, Corinne De Gregorio, Michael Pfeffer, Verena Schaefer, Gennaro Prota, Alfred Zippelius, Jörg Stelling, Daniel Häussinger, Laura Brunelli, Peter Villalta, Marco Lepore, Enrico Davoli, Silvia Balbo, Lucia Mori, Gennaro De Libero, Nucleobase adducts bind MR1 and stimulate MR1-restricted T cells, 2024, 9, 2470-9468, 10.1126/sciimmunol.adn0126 | |
99. | Chenyang Fan, Xiangdong Yang, Lixiang Yan, Zhexin Shi, Oxidative stress is two‐sided in the treatment of acute myeloid leukemia, 2024, 13, 2045-7634, 10.1002/cam4.6806 | |
100. | Jacques Dupuy, Edwin Fouché, Céline Noirot, Pierre Martin, Charline Buisson, Françoise Guéraud, Fabrice Pierre, Cécile Héliès-Toussaint, A dual model of normal vs isogenic Nrf2-depleted murine epithelial cells to explore oxidative stress involvement, 2024, 14, 2045-2322, 10.1038/s41598-024-60938-2 | |
101. | Priya Borah, Hemen Deka, Polycyclic aromatic hydrocarbon (PAH) accumulation in selected medicinal plants: a mini review, 2024, 1614-7499, 10.1007/s11356-024-33548-8 | |
102. | Adrian I. Abdo, Zlatko Kopecki, Comparing Redox and Intracellular Signalling Responses to Cold Plasma in Wound Healing and Cancer, 2024, 46, 1467-3045, 4885, 10.3390/cimb46050294 | |
103. | Dioni Arrieche, Andrés F. Olea, Carlos Jara-Gutiérrez, Joan Villena, Javier Pardo-Baeza, Sara García-Davis, Rafael Viteri, Lautaro Taborga, Héctor Carrasco, Ethanolic Extract from Fruits of Pintoa chilensis, a Chilean Extremophile Plant. Assessment of Antioxidant Activity and In Vitro Cytotoxicity, 2024, 13, 2223-7747, 1409, 10.3390/plants13101409 | |
104. | Feiyi Sun, Yuyang Chen, Kristy W. K. Lam, Wutong Du, Qingqing Liu, Fei Han, Dan Li, Jacky W. Y. Lam, Jianwei Sun, Ryan T. K. Kwok, Ben Zhong Tang, Glutathione‐responsive Aggregation‐induced Emission Photosensitizers for Enhanced Photodynamic Therapy of Lung Cancer, 2024, 1613-6810, 10.1002/smll.202401334 | |
105. | Adam Wroński, Iwona Jarocka-Karpowicz, Arkadiusz Surażyński, Agnieszka Gęgotek, Neven Zarkovic, Elżbieta Skrzydlewska, Modulation of Redox and Inflammatory Signaling in Human Skin Cells Using Phytocannabinoids Applied after UVA Irradiation: In Vitro Studies, 2024, 13, 2073-4409, 965, 10.3390/cells13110965 | |
106. | Palma Fedele, Anna Natalizia Santoro, Francesca Pini, Marcello Pellegrino, Giuseppe Polito, Maria Chiara De Luca, Antonietta Pignatelli, Michele Tancredi, Valeria Lagattolla, Alessandro Anglani, Chiara Guarini, Antonello Pinto, Pietro Bracciale, Immunonutrition, Metabolism, and Programmed Cell Death in Lung Cancer: Translating Bench to Bedside, 2024, 13, 2079-7737, 409, 10.3390/biology13060409 | |
107. | Ana Valenta Šobot, Dunja Drakulić, Ana Todorović, Marijana Janić, Ana Božović, Lidija Todorović, Jelena Filipović Tričković, Gentiopicroside and swertiamarin induce non-selective oxidative stress-mediated cytotoxic effects in human peripheral blood mononuclear cells, 2024, 00092797, 111103, 10.1016/j.cbi.2024.111103 | |
108. | Arno G. Siraki, Lars-Oliver Klotz, 2024, 9780128012383, 10.1016/B978-0-323-95488-4.00062-0 | |
109. | Ismahane Abdelaziz, Abdelkader Bounaama, Bahia Djerdjouri, Zine-Charaf Amir-Tidadini, Low-dose dimethylfumarate attenuates colitis-associated cancer in mice through M2 macrophage polarization and blocking oxidative stress, 2024, 0041008X, 117018, 10.1016/j.taap.2024.117018 | |
110. | Geou-Yarh Liou, Reauxqkwuanzyiia C’lay-Pettis, Sravankumar Kavuri, Involvement of Reactive Oxygen Species in Prostate Cancer and Its Disparity in African Descendants, 2024, 25, 1422-0067, 6665, 10.3390/ijms25126665 | |
111. | Katarzyna Matusik, Katarzyna Kamińska, Aleksandra Sobiborowicz-Sadowska, Hubert Borzuta, Kasper Buczma, Agnieszka Cudnoch-Jędrzejewska, The significance of the apelinergic system in doxorubicin-induced cardiotoxicity, 2024, 1573-7322, 10.1007/s10741-024-10414-w | |
112. | Hengyu Jin, Jianxin Liu, Diming Wang, Antioxidant Potential of Exosomes in Animal Nutrition, 2024, 13, 2076-3921, 964, 10.3390/antiox13080964 | |
113. | Farha Shahabuddin, Samina Naseem, Tauseef Alam, Aijaz Ahmed Khan, Farah Khan, Chronic aluminium chloride exposure induces redox imbalance, metabolic distress, DNA damage, and histopathologic alterations in Wistar rat liver, 2024, 0748-2337, 10.1177/07482337241269784 | |
114. | Jayachithra Ramakrishna Pillai, Adil Farooq Wali, Pooja Shivappa, Sirajunisa Talath, Sabry M. Attia, Ahmed Nadeem, Muneeb U. Rehman, Evaluating the anti-cancer potential and pharmacological in-sights of Physalis angulata Root Extract as a strong candidate for future research, 2024, 22, 1687157X, 100410, 10.1016/j.jgeb.2024.100410 | |
115. | Vilma Dembitz, Hannah Lawson, Richard Burt, Sirisha Natani, Céline Philippe, Sophie C. James, Samantha Atkinson, Jozef Durko, Lydia M. Wang, Joana Campos, Aoife M. S. Magee, Keith Woodley, Michael J. Austin, Ana Rio-Machin, Pedro Casado, Findlay Bewicke-Copley, Giovanny Rodriguez Blanco, Diego Pereira-Martins, Lieve Oudejans, Emeline Boet, Alex von Kriegsheim, Juerg Schwaller, Andrew J. Finch, Bela Patel, Jean-Emmanuel Sarry, Jerome Tamburini, Jan Jacob Schuringa, Lori Hazlehurst, John A. Copland III, Mariia Yuneva, Barrie Peck, Pedro Cutillas, Jude Fitzgibbon, Kevin Rouault-Pierre, Kamil Kranc, Paolo Gallipoli, Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation, 2024, 0887-6924, 10.1038/s41375-024-02390-9 | |
116. | Sinemyiz Atalay Ekiner, Agnieszka Gęgotek, Elżbieta Skrzydlewska, Inflammasome activity regulation by PUFA metabolites, 2024, 15, 1664-3224, 10.3389/fimmu.2024.1452749 | |
117. | Giacomo G. Rossetti, Noëlle Dommann, Angeliki Karamichali, Vasilis S. Dionellis, Ainhoa Asensio Aldave, Tural Yarahmadov, Eddie Rodriguez-Carballo, Adrian Keogh, Daniel Candinas, Deborah Stroka, Thanos D. Halazonetis, In vivo DNA replication dynamics unveil aging-dependent replication stress, 2024, 00928674, 10.1016/j.cell.2024.08.034 | |
118. | Natalia Kurhaluk, Piotr Kamiński, Halina Tkaczenko, 2024, Chapter 425, 2731-4561, 10.1007/16833_2024_425 | |
119. | Jian Gao, Linjie Yuan, Huanyu Jiang, Ganggang Li, Yuwei Zhang, Ruijun Zhou, Wenjia Xian, Yutong Zou, Quanyu Du, Xianhua Zhou, Naringenin modulates oxidative stress and lipid metabolism: Insights from network pharmacology, mendelian randomization, and molecular docking, 2024, 15, 1663-9812, 10.3389/fphar.2024.1448308 | |
120. | Ibrahim S Topiwala, Aparna Ramachandran, Meghana Shakthi. A, Ranjini Sengupta, Rajib Dhar, Arikketh Devi, Exosomes and Tumor Virus Interlink: A Complex Side of Cancer, 2024, 03440338, 155747, 10.1016/j.prp.2024.155747 | |
121. | Andrew Chancellor, Daniel Constantin, Qinmei Yang, Vladimir Nosi, José Pedro Loureiro, Rodrigo Colombo, Roman P. Jakob, Daniel Joss, Michael Pfeffer, Giulia De Simone, Aurelia Morabito, Verena Schaefer, Alessandro Vacchini, Laura Brunelli, Daniela Montagna, Markus Heim, Alfred Zippelius, Enrico Davoli, Daniel Häussinger, Timm Maier, Lucia Mori, Gennaro De Libero, The carbonyl nucleobase adduct M3Ade is a potent antigen for adaptive polyclonal MR1-restricted T cells, 2024, 10747613, 10.1016/j.immuni.2024.11.019 | |
122. | Boleslaw T. Karwowski, The Adducts Lipid Peroxidation Products with 2′-DeoxyNucleosides: A Theoretical Approach of Ionisation Potential, 2025, 15, 2076-3417, 437, 10.3390/app15010437 | |
123. | Robert Andrew Brown, 2024, Chapter 8, 978-3-031-73060-3, 247, 10.1007/978-3-031-73061-0_8 | |
124. | Çağla Zübeyde Köprü, Burcu Baba, Dilek Yonar, Zerumbone Induces Apoptosis in Non‐Small‐Cell Lung Cancer via Biomolecular Alterations: A Microscopic and Spectroscopic Study, 2025, 1864-063X, 10.1002/jbio.202400500 | |
125. | ZhV Yavroyan, AG Hovhannisyan, NR Hakobyan, ES Gevorgyan, Effect of cisplatin on lipid peroxidation in the whole blood and plasma of female rats, 2025, 2453-6725, 10.2478/afpuc-2024-0014 | |
126. | Saeed Alshahrani, Mohammad Ashafaq, Abdulmajeed M. Jali, Yosif Almoshari, Mohammad Intakhab Alam, Hamad Al Shahi, Ayed A. Alshamrani, Sohail Hussain, Nephrotoxic effect of cypermethrin ameliorated by nanocurcumin through antioxidative mechanism, 2025, 0028-1298, 10.1007/s00210-025-03825-5 | |
127. | Sara Ilari, Stefania Proietti, Francesca Milani, Laura Vitiello, Carolina Muscoli, Patrizia Russo, Stefano Bonassi, Dietary Patterns, Oxidative Stress, and Early Inflammation: A Systematic Review and Meta-Analysis Comparing Mediterranean, Vegan, and Vegetarian Diets, 2025, 17, 2072-6643, 548, 10.3390/nu17030548 | |
128. | Chonnikarn Jirasit, Panida Navasumrit, Krittinee Chaisatra, Chalida Chompoobut, Somchamai Waraprasit, Varabhorn Parnlob, Mathuros Ruchirawat, Genotoxicity and fibrosis in human hepatocytes in vitro from exposure to low doses of PBDE-47, arsenic, or both chemicals, 2025, 00092797, 111410, 10.1016/j.cbi.2025.111410 | |
129. | Daniel A. Kasal, Viviane Sena, Grazielle Vilas Bôas Huguenin, Andrea De Lorenzo, Eduardo Tibirica, Microvascular endothelial dysfunction in vascular senescence and disease, 2025, 12, 2297-055X, 10.3389/fcvm.2025.1505516 | |
130. | Teresa Catalano, Federico Selvaggi, Roberto Cotellese, Gitana Maria Aceto, The Role of Reactive Oxygen Species in Colorectal Cancer Initiation and Progression: Perspectives on Theranostic Approaches, 2025, 17, 2072-6694, 752, 10.3390/cancers17050752 | |
131. | Nirmal Manhar, Sumeet Kumar Singh, Poonam Yadav, Manish Bishnolia, Amit Khurana, Jasvinder Singh Bhatti, Umashanker Navik, Methyl Donor Ameliorates CCl4‐Induced Nephrotoxicity by Inhibiting Oxidative Stress, Inflammation, and Fibrosis Through the Attenuation of Kidney Injury Molecule 1 and Neutrophil Gelatinase‐Associated Lipocalin Expression, 2025, 39, 1095-6670, 10.1002/jbt.70188 | |
132. | B. Perez-Montero, M. L. Fermin-Rodriguez, M. Portero-Fuentes, J. Sarquis, S. Caceres, J. C. Illera del Portal, L. de Juan, G. Miro, F. Cruz-Lopez, Malondialdehyde (MDA) and 8-hydroxy-2’-deoxyguanosine (8-OHdG) levels in canine serum: establishing reference intervals and influencing factors, 2025, 21, 1746-6148, 10.1186/s12917-025-04614-1 | |
133. | Sathiyan Niranjana, Anantha Udupa Prarthana, Aiswarya Ganapathisankarakrishnan, Dhakshinamoorthy Sundaramurthi, Vellingiri Vadivel, Comparative analysis of in vitro antioxidant and wound healing activities of Indian paalai plant extracts and investigation of their phytochemical profile by GC-MS, 2025, 7, 29501997, 100202, 10.1016/j.prenap.2025.100202 | |
134. | Fabián Delgado Rodríguez, Gabriela Azofeifa, Silvia Quesada, Nien Tzu Weng Huang, Arlene Loría Gutiérrez, María Fernanda Morales Rojas, Influence of Plant Part Selection and Drying Technique: Exploration and Optimization of Antioxidant and Antibacterial Activities of New Guinea Impatiens Extracts, 2025, 14, 2223-7747, 1092, 10.3390/plants14071092 | |
135. | Asha Ashraf, Bernd Zechmann, Erica D. Bruce, Hypoxia-inducible factor 1α modulates acrolein-induced cellular damage in bronchial epithelial cells, 2025, 515, 0300483X, 154158, 10.1016/j.tox.2025.154158 | |
136. | Taiyue Jin, Seulbi Lee, Juhee Seo, Shinhee Ye, Soontae Kim, Jin-Kyoung Oh, Seyoung Kim, Byungmi Kim, Long-term ambient ozone exposure and lung cancer mortality: a nested case-control study in Korea, 2025, 02697491, 126299, 10.1016/j.envpol.2025.126299 |
day | Feb 21 | Feb 22 | Feb 23 | Feb 24 | Feb 25 |
R | 20 | 77 | 146 | 229 | 322 |
day | Feb 26 | Feb 27 | Feb 28 | Feb 29 | Mar 1 |
R | 400 | 650 | 888 | 1128 | 1694 |
day | Mar 2 | Mar 3 | Mar 4 | Mar 5 | Mar 6 |
R | 1835 | 2502 | 3089 | 3858 | 4636 |
day | Mar 7 | Mar 8 | Mar 9 | Mar 10 | Mar 11 |
R | 5883 | 7375 | 9172 | 10149 | 12462 |
day | Mar 12 | Mar 13 | Mar 14 | Mar 15 | Mar 16 |
R | 15113 | 17660 | 21157 | 24747 | 27980 |
day | Mar 17 | Mar 18 | Mar 19 | Mar 20 | Mar 21 |
R | 31506 | 35713 | 41035 | 47021 | 53578 |
day | Mar 22 | Mar 23 | Mar 24 | Mar 25 | Mar 26 |
R | 59138 | 63927 | 69176 | 74386 | 80539 |
day | Mar 27 | Mar 28 | Mar 29 | Mar 30 | Mar 31 |
R | 86498 | 92472 | 97689 | 101739 | 105792 |
day | Apr 1 | Apr 2 | Apr 3 | Apr 4 | Apr 5 |
R | 110574 | 115242 | 119827 | 124632 | 128948 |
day | Apr 6 | Apr 7 | Apr 8 | Apr 9 | Apr 10 |
R | 132547 | 135586 | 139422 | 143626 | 147577 |
day | Apr 11 | Apr 12 | Apr 13 | Apr 14 | Apr 15 |
R | 152271 | 156363 | 159516 | 162488 | 165155 |
day | Apr 16 | Apr 17 | Apr 18 | Apr 19 | Apr 20 |
R | 168941 | 172434 | 175925 | 178972 | 181228 |
day | Apr 21 | Apr 22 | Apr 23 | Apr 24 | Apr 25 |
R | 183957 | 187327 | 189973 | 192994 | 195351 |
day | Apr 26 | Apr 27 | Apr 28 | Apr 29 | Apr 30 |
R | 197675 | 199414 | 201505 | 203591 | 205463 |
day | May 1 | May 2 | May 3 | May 4 | May 5 |
R | 207428 | 209328 | 210717 | 211938 | 213013 |
day | May 6 | May 7 | May 8 | May 9 | May 10 |
R | 214457 | 215858 | 217185 | 218268 | 219070 |
day | May 11 | May 12 | May 13 | May 14 | May 15 |
R | 219814 | 221216 | 222104 | 223096 | 223885 |
QF | β | 1/3 | 1/4 | 1/5 | 1/6 | 1/7 | 1/8 | 1/9 | 1/10 |
I0 | 2900 | 3866 | 4833 | 5799 | 6766 | 7732 | 8699 | 9665 | |
ϕ | 0.25 | 0.33 | 0.42 | 0.50 | 0.58 | 0.67 | 0.75 | 0.83 | |
S0/γ | 1.25 | 1.33 | 1.42 | 1.50 | 1.58 | 1.67 | 1.75 | 1.83 | |
EF | β | 1/3 | 1/4 | 1/5 | 1/6 | 1/7 | 1/8 | 1/9 | 1/10 |
I0 | 2581 | 3441 | 4301 | 5162 | 6022 | 6882 | 7743 | 8602 | |
ϕ | 0.55 | 0.73 | 0.91 | 1.09 | 1.28 | 1.46 | 1.64 | 1.82 | |
S0/γ | 1.55 | 1.73 | 1.91 | 2.09 | 2.28 | 2.46 | 2.64 | 2.82 |
r | I∗ | t∗ | R∞/S0 | U∞/S0 | S∞/S0 | |
ξ=1/10 | 1.0 | 1.3∗106 | 57 | 0.10 | 0.89 | 0.01 |
η=1/21 | 0.8 | 1.0∗106 | 70 | 0.10 | 0.87 | 0.03 |
0.6 | 6.5∗105 | 95 | 0.09 | 0.82 | 0.09 | |
0.4 | 2.5∗105 | 167 | 0.07 | 0.65 | 0.28 |
r | te | R∞/S0 | U∞/S0 | |
ξ=1/10 | 0.2 | 539 | 1.02∗10−4 | 9.17∗10−3 |
η=1/21 | 0.1 | 107 | 2.67∗10−4 | 2.40∗10−3 |
0.05 | 66 | 2.09∗10−4 | 1.88∗10−3 | |
0.02 | 50 | 1.88∗10−4 | 1.69∗10−3 | |
0.01 | 46 | 1.82∗10−4 | 1.64∗10−3 |
r | te | R∞/S0 | r | te | R∞/S0 |
0.20 | 57 | 2.29∗10−4 | 0.20 | 41 | 1.77∗10−4 |
0.10 | 49 | 1.98∗10−4 | 0.10 | 37 | 1.58∗10−4 |
0.05 | 46 | 1.87∗10−4 | 0.05 | 35 | 1.51∗10−4 |
0.02 | 44 | 1.81∗10−4 | 0.02 | 34 | 1.47∗10−4 |
0.01 | 44 | 1.79∗10−4 | 0.01 | 34 | 1.46∗10−4 |
day | Feb 21 | Feb 22 | Feb 23 | Feb 24 | Feb 25 |
R | 20 | 77 | 146 | 229 | 322 |
day | Feb 26 | Feb 27 | Feb 28 | Feb 29 | Mar 1 |
R | 400 | 650 | 888 | 1128 | 1694 |
day | Mar 2 | Mar 3 | Mar 4 | Mar 5 | Mar 6 |
R | 1835 | 2502 | 3089 | 3858 | 4636 |
day | Mar 7 | Mar 8 | Mar 9 | Mar 10 | Mar 11 |
R | 5883 | 7375 | 9172 | 10149 | 12462 |
day | Mar 12 | Mar 13 | Mar 14 | Mar 15 | Mar 16 |
R | 15113 | 17660 | 21157 | 24747 | 27980 |
day | Mar 17 | Mar 18 | Mar 19 | Mar 20 | Mar 21 |
R | 31506 | 35713 | 41035 | 47021 | 53578 |
day | Mar 22 | Mar 23 | Mar 24 | Mar 25 | Mar 26 |
R | 59138 | 63927 | 69176 | 74386 | 80539 |
day | Mar 27 | Mar 28 | Mar 29 | Mar 30 | Mar 31 |
R | 86498 | 92472 | 97689 | 101739 | 105792 |
day | Apr 1 | Apr 2 | Apr 3 | Apr 4 | Apr 5 |
R | 110574 | 115242 | 119827 | 124632 | 128948 |
day | Apr 6 | Apr 7 | Apr 8 | Apr 9 | Apr 10 |
R | 132547 | 135586 | 139422 | 143626 | 147577 |
day | Apr 11 | Apr 12 | Apr 13 | Apr 14 | Apr 15 |
R | 152271 | 156363 | 159516 | 162488 | 165155 |
day | Apr 16 | Apr 17 | Apr 18 | Apr 19 | Apr 20 |
R | 168941 | 172434 | 175925 | 178972 | 181228 |
day | Apr 21 | Apr 22 | Apr 23 | Apr 24 | Apr 25 |
R | 183957 | 187327 | 189973 | 192994 | 195351 |
day | Apr 26 | Apr 27 | Apr 28 | Apr 29 | Apr 30 |
R | 197675 | 199414 | 201505 | 203591 | 205463 |
day | May 1 | May 2 | May 3 | May 4 | May 5 |
R | 207428 | 209328 | 210717 | 211938 | 213013 |
day | May 6 | May 7 | May 8 | May 9 | May 10 |
R | 214457 | 215858 | 217185 | 218268 | 219070 |
day | May 11 | May 12 | May 13 | May 14 | May 15 |
R | 219814 | 221216 | 222104 | 223096 | 223885 |
QF | β | 1/3 | 1/4 | 1/5 | 1/6 | 1/7 | 1/8 | 1/9 | 1/10 |
I0 | 2900 | 3866 | 4833 | 5799 | 6766 | 7732 | 8699 | 9665 | |
ϕ | 0.25 | 0.33 | 0.42 | 0.50 | 0.58 | 0.67 | 0.75 | 0.83 | |
S0/γ | 1.25 | 1.33 | 1.42 | 1.50 | 1.58 | 1.67 | 1.75 | 1.83 | |
EF | β | 1/3 | 1/4 | 1/5 | 1/6 | 1/7 | 1/8 | 1/9 | 1/10 |
I0 | 2581 | 3441 | 4301 | 5162 | 6022 | 6882 | 7743 | 8602 | |
ϕ | 0.55 | 0.73 | 0.91 | 1.09 | 1.28 | 1.46 | 1.64 | 1.82 | |
S0/γ | 1.55 | 1.73 | 1.91 | 2.09 | 2.28 | 2.46 | 2.64 | 2.82 |
r | I∗ | t∗ | R∞/S0 | U∞/S0 | S∞/S0 | |
ξ=1/10 | 1.0 | 1.3∗106 | 57 | 0.10 | 0.89 | 0.01 |
η=1/21 | 0.8 | 1.0∗106 | 70 | 0.10 | 0.87 | 0.03 |
0.6 | 6.5∗105 | 95 | 0.09 | 0.82 | 0.09 | |
0.4 | 2.5∗105 | 167 | 0.07 | 0.65 | 0.28 |
r | te | R∞/S0 | U∞/S0 | |
ξ=1/10 | 0.2 | 539 | 1.02∗10−4 | 9.17∗10−3 |
η=1/21 | 0.1 | 107 | 2.67∗10−4 | 2.40∗10−3 |
0.05 | 66 | 2.09∗10−4 | 1.88∗10−3 | |
0.02 | 50 | 1.88∗10−4 | 1.69∗10−3 | |
0.01 | 46 | 1.82∗10−4 | 1.64∗10−3 |
r | te | R∞/S0 | r | te | R∞/S0 |
0.20 | 57 | 2.29∗10−4 | 0.20 | 41 | 1.77∗10−4 |
0.10 | 49 | 1.98∗10−4 | 0.10 | 37 | 1.58∗10−4 |
0.05 | 46 | 1.87∗10−4 | 0.05 | 35 | 1.51∗10−4 |
0.02 | 44 | 1.81∗10−4 | 0.02 | 34 | 1.47∗10−4 |
0.01 | 44 | 1.79∗10−4 | 0.01 | 34 | 1.46∗10−4 |